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                               PLAGIARISM REPORT 
 
 
ABBREVIATIONS 
   
 TSH - Thyroid Stimulating Hormone 
 T3 - Triiodothyronine 
 T4 - Tetraiodothyronine 
 MIT - Mono-Iodo-Thyronine 
 DIT - Di-Iodo-Thyronine 
 TRH - Thyrotropin Releasing Hormone 
 TG - Thyroglobulin 
 PRL - Prolactin 
 LH - Luteinizing Hormone 
 FSH - Follicle Stimulating Hormone 
 GnRH - Gonadotropin Releasing Hormone 
 BBT - Basal Body Temperature 
 USG - UltraSonography 
 HSG - HysteroSalpingography 
 TVS  - Trans-Vaginal Sonography 
 SIS - Saline Infusion Sonography 
 MRI - Magnetic Resonance Imaging 
 BMI - Body Mass Index 
 W/H - Weight For Height 
 CYP - Cytochrome P 
 PCOS - Polycystic Ovary Syndrome 
 LUFS - Luteinized Unruptured Follicle Syndrome 
 HPA - Hypothalamo Pituitary Axis 
 OCP - Oral Contraceptive Pill 
 SHBG - Sex Hormone Binding Globulin 
 ITP - Immune Thrombocytopenic Purpura 
 AITD - Auto Immune Thyroid Disease 
 TPO - Thyroid Peroxidase 
 Na/I - Sodium Iodide 
 MI - Myocardial Infarction 
 DM - Diabetes mellitus 
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Thyroid disorder which is either undiagnosed or untreated can be a 
cause for infertility as well as sub fertility. These conditions have got important 
medical, economical and psychological implications in our society. Thyroid 
dysfunction can affect fertility in various ways leading to luteal phase defects, 
raised prolactin level, anovulatory cycles and sex hormone imbalance. So  
normal thyroid function is necessary for conception and to sustain a healthy 
pregnancy even in the earlier days after conception. Thyroid evaluation should 
be done in any woman who wants to get pregnant with history of thyroid    
problem or irregular menstrual cycle or had repeated miscarriages or if she is 
unable to conceive after one year of unprotected sexual intercourse. The    
comprehensive thyroid function tests should include free T3, free T4 and TSH. 
 
            Prevalence of hypothyroidism in reproductive age group is 2 -4 % and 
has been shown to be the cause of infertility and habitual abortion.  A slight  
increase in TSH levels with normal T3 and T4 indicates  subclinical              
hypothyroidism, whereas high TSH levels accompanied by low T3 and  T4   
indicate clinical  hypothyroidism. Sub clinical hypothyroidism is more     
common. It can affect ovulation directly or by causing raise in prolactin  levels. 
It is of prime importance to diagnose and treat subclinical  hypothyroidism 
early for achieving conception and to maintain it, unless there are other inde-
pendent risk factors. Many infertile women with  hypothyroidism   may have 
increased production of thyrotropin releasing hormone, which may result in as-
sociated  hyperprolactinemia thereby resulting  in ovulatory        dysfunction. 
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In the presence of raised prolactin,  check thyroid hormone levels first and  
treatment should be  given to correct hypothyroidism if there is any       before 
evaluating other causes of raised prolactin. Measurement of TSH and Prolactin 
is routinely done as a part of infertility workup. Due to lack of     population 
based infertility data of women with subclinical hypothyroidism in our state, I 
planned to study the prevalence of hypothyroidism in infertile women as well 
as to assess their response to drug treatment for  hypothyroidism. 
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             AIM OF THE STUDY 
 
 
• To assess the prevalence of clinical and subclinical hypothyroidism in 
infertile women. 
• To evaluate the response of treatment for hypothyroidism on infertility. 
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   MATERIALS AND METHODS 
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               150 primary infertile  females aged 20-40 years consulting at Gov-
ernment RSRM  Hospital between September 2014 and September 2015 were 
considered for the study purpose.  
Initial Assessment 
                 Initial encounter of physician with infertile couple sets the tone for 
subsequent evaluation and treatment. Complete medi-
cal,surgical,gynaecological history were obtained from the female. Male factor 
infertility was evaluated. Reproductive function of either partner was  assessed 
by coital         frequency, dyspareunia and sexual dysfunction. 
                Physical examination of female included height,weight,BMI,body 
habitus,hair distribution,thyroid gland and pelvic examination. Male patients 
were referred to urologists if any significant findings were there in history. 
                Basic investigations including semen analysis,confirmation of      
ovulation,documentation of tubal patency were  done before starting       infer-
tility treatment. 
              Infertile women with both clinical and subclinical hypo-thyroidism 
were included. 
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             All females were systematically screened on the third day of their  
menstrual cycle for serum  TSH and free T4 levels using  3rd generation electro 
chemiluminescence immunoassay. 
                         
                        Reference values:     Serum TSH   < 2.5mIU/L 
                                                          Free T4         = 0.8-2 ng/dL 
             Serum Prolactin was also estimated during the first visit 
                           Reference value : 1.9 – 25 ng/ml 
            Anti TPO antibodies were determined using RIA 
                             Reference Value  < 35mIU/L 
INCLUSION CRITERIA: 
¾ 20-40 yrs female 
¾ First visit to infertility clinic 
¾ Investigated for TSH and PRL 
EXCLUSION CRITERIA: 
¾ Women with tubal block 
¾ Women with PID 
¾ Women with Endometriosis 
¾ Women with genital TB 
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¾ Women with Liver,Renal,Cardiac diseases 
¾ Women whose husbands have abnormal semen analysis. 
¾ On treatment for hyperprolactinemia. 
              Prospective evaluation of patients meeting inclusion and  exclusion 
criteria done. 
              Infertile women with hypothyroidism alone or with associated         
hyperprolactinemia were given treatment for hypothyroidism with thyroxine 
25-150 micrograms, regulating the dose by serial serum TSH monitoring at 6-8 
weeks interval. 
                The effectiveness and outcome of the treatment studied by  assessing 
the fertility rate over 3 months to 1 year of treatment. 
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    REVIEW OF LITERATURE 
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INFERTILITY 
 
                 Infertility is defined as the failure of conception following 1year of 
unprotected sexual intercourse1. It is classified as Primary and Secondary       
Infertility2.  90% of women should conceive within 12 months of unprotected  
intercourse. 
       According to International Committee for monitoring Assisted     
Reproductive Technology and WHO, infertility is a disease of reproductive 
system defined by failure to achieve a clinical pregnancy after 12 months or 
more of regular unprotected sexual intercourse. (Zegers Hochschild et al 
2009). 
               Infertility is also defined as absence of live birth in a sexually active 
non contracepting female.(Larsen,2005)   
      Global estimates suggest that nearly 72.4 million couples experience 
fertility problems.(Boivin et al 2007) 
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                               CAUSES OF INFERTILITY 
 
1.Relative Prevalence of the etiologies of Infertility 
 Male Factor     20-30% 
 Both Male and Female Factors   10-40% 
 Female Factor     40-55% 
 Unexplained Infertility    10-20% 
 
2.Approximate Prevalence of the causes of infertility in females 
 Ovulatory Dysfunction    20-40% 
 Tubal/Peritoneal Factors    20-40% 
 Miscellaneous Causes    10-15% 
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                INFERTILITY WORKUP 
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FEMALE INFERTILITY    
                     In 2010, 48.5 million infertile couples worldwide were          
attributed to female infertility.(Mascarenhas, M.N.Flaxman, Stevens 
2012)  
            Prevalence of female infertility varies worldwide (3-7%).          
Consequences of infertility are social repercussions,personal sufferings, 
psychological effects, sexual dysfunction and clinical depression.   
             Incidence of female infertility is on the rise. Currently it is 10-
20% 
FACTORS ASSOCIATED WITH FEMALE INFERTILITY 
¾ Advanced Age 
¾ Emotional Stress  
¾ High BMI 
¾ Ovarian Factors 
¾ Tubal and Peritoneal Factors 
¾ Pelvic Factors 
¾ Uterine Factors 
¾ Hormonal Disorders 
¾ Unexplained infertility 
¾ Miscellaneous 
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 Advanced Age(>35 years) 
                With advancing age, the risk of 
                      Unexplained infertility is 1-8% 
           Ovulatory Dysfunction is 0.3% 
           Tubal Dysfunction is 2.2% 
 BMI 
                     Almost 1/5th of infertility happens in either underweight or 
overweight females. Obesity is strongly associated with female infertility. 
Mechanism is largely unknown(fat cells produce estrogen).Underweight 
and overweight individuals may have irregular cycles with anovulation. 
 Emotional Stress 
              Biological interaction between stress and infertility is the result of   
action of stress hormones at the brain level,  HP axis and female   repro-
ductive  organs.Stress causes infertility by altering  HP pathway, affecting 
tubal motility.Stress can cause vaginismus, dyspareunia and frigidity inturn 
leading to infertility.Catecholamines and HPA axis  hormones     interact 
with hormones responsible for normal ovulatory cycle. 
 Ovarian Factors 
             Account for nearly 30% of female infertility.Initial diagnosis is 
either anovulation or oligo-ovulation.Normal menstrual cycle length 
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range is 21-35 days. Cycle length variability attributed to follicular 
phase. Luteal phase is fixed(14 days).There is a possibility of normal 
cycles to be anovulatory also5.Mood changes, bloating, premenstrual 
breast swelling predict ovulatory cycle. 
              
  Relative Hormonal fluctuations in a normal,ovulatory,28-day menstrual cycle 
 
 
Methods to identify ovulation: 
1. Basal Body Temperature: 
        Daily recording of rectal/oral temperature by the patient after get-
ting up in the early morning .BBT rise by 0.5 to 1 degree F, which is due 
to progesterone influence.Daily charting shows biphasic pattern in 
women with ovulatory cycle6. 
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2. Cervical Mucus 
          Fertile window- mucus slippery and clear 
          Luteal phase    - mucus dry and sticky 
3. LH Monitoring 
           LH detected in urine 2 hours following peak of LH 
surge.Ovulation will occur within in the next 2 days of urinary detec-
tion.Not useful in patients with irregular cycles.Detected by ELISA 35-
50 mIU/ml as threshold7,8. 
4. Midluteal Serum Progesterone 
           Peak Progesterone secretion seen in the midluteal phase i.e., Day 
21-23 of  28 day cycle. Levels > 3ng/ml confirms ovulation9. 
5. USG 
           Ovulation indicated by decrease in size of  monitored follicle and 
fluid collection in cul-de-sac. Pre-ovulatory follicular measurement in 
normal cycle 17-19 mm10,11. 
Polycystic Ovarian Syndrome 
            First described by Stein Levinthal in 1935. 
Leading cause of female infertility.(Goldenberg N,Glueck 2008) 
            Prevalent in 5-10% of females in reproductive age group. 
  Most commom cause of oligo-ovulation or anovulation in females   
presenting with infertility12. Accounts for > 75% of cases of anovulatory 
infertility.(Gorry A, White D.M, Frank S August 2006) 
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              Diagnosis is made by excluding other medical conditions and 
other causes of hyperandrogenism. 
Rotterdam’s Diagnostic Criteria for PCOS(2003) 
 Oligo-ovulation or Anovulation 
 Hyperandrogenism or Hyperandrogenemia 
 Sonological evidence of PCOS 
 
                               Elevated LH/FH ratio and hyperinsulinemia are not required 
for diagnosis or treatment.Obesity is found to be associated with more than   
50%  of  patients. 
Features of  Hyperinsulinemia: 
              BMI > 27 kg/sq.m 
              W/H > 0.85 
              Waist > 100 cms 
              Acanthosis nigricans 
              Numerous achrochordons 
Pathophysiology of PCOS 
               Insulin resistance results in compensatory hyperinsulinemia,which 
stimulates ovarian androgen production in an ovary genetically predisposed to 
PCOS. Arrest of follicular development and anovulation could be caused by the 
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abnormal secretion of gonadotropins such as follicle stimulating                   
hormone(FSH) or luteinizing hormone(LH),intra ovarian androgen                
excess,direct effects of insulin or a combination of the above mentioned       
factors. Insulin resistance may also lead to hyperglycemia and an adverse     
profile of cardiovascular risk factors13. 
 
   Figure: Pathophysiological characteristics of PCOS 
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                             Hyperandrogenism and anovulation are due to abnormality in 
four endocrinologically active component 
                      1.Ovarian and Adrenal 
Dysregulation of CYP17 leads to elevated Testosterone > 2 upper    
normal range14 
                     2 .Peripheral  Component 
 5 alpha reductase activity in skin incresed leading to Hirsutism. Periph-
eral aromatisation results in elevated BMI. Estrogen metabolism is altered15. 
                      3.Hypothalamic Pituitary component-     
Increased LH pulse frequency resulting in raised LH/FSH ratio. 25%  
increase in serum prolactin observed16. 
Ovarian Reserve:  
            Refers to nongrowing/resting primordial follicle population in ovaries-
presumably determines reproductive potential of oocytes. Estimated by day 2 
FSH and antral follicular count. 
Day2 FSH: >8IU/L is the cut off. Pregnancy rates decrease by 7% for every 
unit rise in FSH. 
AFC: Detect number of follicles in early follicular phase by TVS in both ova-
ries. Size of follicle 2-10 mm. Cut off  -4. 
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 Tubal and Peritoneal Factors 
                 Accounts for 25-35% of infertility(Bardawil MD,Tarek,Richard 
Scott) 
            Non infectious Causes 
                Tubal Endometriosis,tubal polyp,tubal spasm,intra tubal mucus     
debris17. 
           Infectious Causes 
               Chlamydia trachomatis,Neisseria gonorrhoea are the common    
pathogens associated with PID18.(Ljubin-Sternak,Suncanica,Mestrovic 
2014) 
   HSG 
                Performed prior to ovulation between day 7-12 to avoid potential 
pregnancy loss.In dorsal lithotomy position,metal cannula is inserted through 
the cervix besides the internal os and contrast dye is injected. Under             
fluoroscopy, uterine cavity,fallopian tube architecture and tubal patency are 
visualized19,20. 
               Complications: Oil based contrast can cause oil embolism but has 
higher rates of pregnancy following HSG when compared to water based    
contrast21,22. Anaphylactic  reactions in Iodine allergic patients. Uterine         
perforation, cervical    laceration, vascular intravasation ,vasovagal reactions 
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are rare.Antibiotic prophylaxis with Doxycycline is must.HSG contra-indicated 
in Hydrosalpinx. 
Laparoscopy: 
                      Gold standard for diagnosing tubal and peritoneal disease. Pelvic 
adhesions are best visualised under laparoscopy.(Kodaman PH,Arici A,Seli E 
June 2004) 
Chromopertubation: 
                      Indigo Carmine Dye is injected trans-cervically and tubal 
patency, fimbrial architecture visualised directly23.Concurrent management of 
intra mural/ sub serous fibroids/peritubal/periovarian adhesions and              
endometriosis are possible. 
Advances: 
    Falloscopy with Hysteroscopy allows direct fibre-optic visualisation of tubal 
ostia24,25. 
  Sonosalpingography: 
    Non invasive method to diagnose fallopian tube obstruction. 
 UTERINE FACTORS: 
                     Accounts for 15% of infertility26. 
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               Uterine cavity abnormalities include endometrial polyps, endometrial 
hyperplasia, submucous myomas, intrauterine synechiae, congenital uterine 
anamolies. 
 
 Mullerian Anomalies: 
             Raga F,Bauset C,Pellicer A 1997,demonstrated reproductive impact 
of congenital mullerian anomalies. 
Anomalies include, 
         1.Unicornuate uterus 
         2.Bicornuate uterus 
        3.Arcuate uterus 
        4.Uterine didelphys 
        5.Septate uterus 
Leiomyoma 
          Alters uterine contractility,impaired gamete transport,endometrial dys-
function. 
Endometrial Polyp 
          Disorder endometrial receptivity 
Intra-uterine Synechiae 
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          Severe trauma to basalis layer with subsequent tissue bridge formation 
following extensive evacuation of uterine cavity in case of incomplete preg-
nancy loss,PPH,genital TB.(Magos A 2002) 
 
 HSG 
          Shows general configuration of uterine cavity and indicates endometrial 
lesion as filling defects or irregularities in intra-uterine wall. 
 Hysteroscopy 
          Ideal for uterine cavity evaluation. Performed in mid-follicular phase. 
 TVS 
          96.5% NPV and 75% PPV for intra-cavitary polyps 
 SIS 
        Trans-cervical instillation of saline during TVS distends the uterine cavity 
and delineates the endometrium. Performed during follicular phase. 
 Pelvic MRI 
         Gold standard to diagnose rudimentary uterine horns and multiple        
fibroids. 
 PELVIC FACTORS 
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                 Endometriosis accounts for 6-10% of infertility in reproductive age 
females27. Infertility occurs in upto half of women suffering from endometrio-
sis. (Bulletti C,Battostoni S, Borini F August 2010) 
                 Endometrial tissue growing outside the uterine cavity in peritoneum, 
ovaries, recto vaginal septum is called as endometriosis. 
 
 UNEXPLAINED INFERTILITY 
                 30% couple are diagnosed with unexplained infertility28,29.  
Basic infertility evaluation reveals normal semen parameters, evidence of    
ovulation, patent fallopian tubes, no other obvious cause of infertility. 
Causes: 
1. Luteal Phase Defect 
         Failure to develop fully mature secretory endometrium during              
implantation window due to inadequate production of progesterone/ improper 
GnRH pulsatility/ inadequate endometrial receptivity to progesterone causes 
luteal phase defect.Diagnosed by shortened luteal phase < 14 days, low mid-
luteal progesterone < 5-10 ng/ml30,31. 
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   2.  LUFS: Luteinisation of a follicle that has failed to rupture and release its 
oocyte with normal menstrual cycle with infertility. Accounts for 25% of      
unexplained infertility32. 
   3.  Immunologic Factors: Serum APLA/ATA/Anti-sperm antibodies33,34. 
   4.  Decreased Endometrial perfusion 
   5. Infections 
     6. Undiagnosed Pelvic pathology 
     7. Occult male or oocyte factor 
 HORMONAL DISORDERS: 
               HYPOGONADOTROPIC HYPOGONADISM: 
                   Dysfunction within HPA axis. Anovulation in the presence of     
decreased serum LH, FSH, estradiol levels defines hypogonadotropic           
hypogonadism. 
                  Causes: Craniopharyngiomas, pituitary adenomas, arteriovenous 
malformations, central space occupying lesions, chronic illness, stress, ano-
rexia, excessive exercise, decreased BMI, congenital hypothalamic failure- 
kallmann syndrome. 
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       HYPERPROLACTINEMIA:   
                 Prolactin first identified as anterior pituitary hormone in1933. It has 
199 amino acids. A single gene on chromosome 6 encodes prolactin35. Most    
potent form of prolactin is 23,000 dalton non glycosylated form36. 
               Prolactin is mainly under inhibitory control of dopamine that is       
secreted from tuberoinfundibular dopaminergic neurons into portal               
hypophyseal vessels37,38.  
TRH causes prolactin release when present at supraphysiological levels-
primary hypothyroidism. Most common cause of hyperprolactinemia – phar-
mocologic –antipsychotics,  antidopaminergic agents. 
Normal serum prolactin level 5-25ng/ml throughout normal menstrual cycle. 
Prolactin pulsatility: 14pulses/24 hrs in late follicular phase 
                                  9pulses/ 24 hrs in late luteal phase 
                                  Pulse amplitude increases from early to late follicular 
phase to luteal phase39,40. 
Clinical features: Amenorrhoea/ Galactorrhoea  
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                           Figure: Hyperprolactinemia Workup 
THYROID DISORDERS 
                         Most common endocrine condition affecting females of         
reproductive age group41. Thyroid Hormone acts systematically to control      
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metabolism. Thyroid gland function is under the control of Hypothalamo      
Pituitary Axis. Hence has great impact on reproduction before,during and after 
pregnancy. 
 
 Figure: Regulation of Thyroid Hormone release.TRH-Thyrotropin Releasing 
Hormone, TSH- Thyroid Stimulating Hormone,T3-Triiodothyronine,T4-
Tetraiodo thyronine 
THYROID HORMONES 
                        Iodide is a critical component of the class of hormones known 
as thyronines among which most important are Tri-iodothyronine(T3) and 
Tetra-iodo thyronine(T4).Dietary iodide is transported to thyroid follicular cells 
for the synthesis of these hormones.Sodium iodide symporter is a key molecule 
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in thyroid function- for accumulation of Iodine in thyrocyte against an electro 
chemical gradient.NIS requires energy which is supplied by Na-K-ATPase and 
iodine uptake is stimulated by TSH or Thyrotropin.TPO oxidises iodide near 
the cell colloid surface and incorporates it into tyrosyl residues within the    
thyroglobulin molecule;which results in the formation of MIT and DIT. T3 and 
T4 formed by secondary coupling of MIT and DIT are catalysed by TPO.TPO 
is a membrane bound  heme containing oligomer, localised in Rough            
Endoplasmic Reticulum, Golgi complex and follicular cell                        
surface. Thyroglobulin storage capacity- maintains euthyroid state for nearly 2 
months without formation of new thyroid hormones.Thyroid antimicrosomal 
Antibodies are directed against TPO enzyme42,43. 
                              TSH regulates thyroidal iodine metabolism by activation of 
adenylate cyclase.This facilitates endocytosis as a component of iodide uptake 
digestion of  TG containing colloid and release of thyroid hormones 
T3/T4/reverse T3. T4 is released  40-100 times more than T3 release from   
thyroid gland.T4 is 70% TBG bound.RT3 levels are 30-50% of T3 and 1% T4. 
T4 is high in circulating storage pool and has slower turnover rate than T3. 
30% of  T4 undergoes peripheral conversion to T3. RT3 participates in the 
conversion of T4 to T3. T3 is the primary physiological hormone at the cellular 
level. T3 binds to nuclear receptor with 10 times greater affinity than T4. 
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Function of thyroid hormones: 
Increased cellular O2 consumption 
Increased heat production 
Increased metabolism of fats/proteins/carbohydrates 
Balances fuel efficiency with performance-Responsible for BMR 
Iodide Requirement44(WHO) 
           150 ug/day in reproductive age group 
           250 ug/day during  pregnancy and lactation 
Evaluation 
           Of the total  T4  and T3 in circulation, approximately 70 to 75% bound 
to TBG. 10 to 15% attached to pre-albumin, 10 to 15% attached to albumin and   
< 5% bound to lipoprotein. Only 0.02% to 0.03% of circulating T4 and 0.2 to 
0.3% of circulating T3 is in unbound state. Total thyroid measurements are  
dependent on TBG which is affected by pregnancy, estrogen                       
therapy, OCPs, Hepatitis, genetic abnormalities of TBG. Thus Free T3/Free T4 
assay are more relevant clinically than Total thyroid hormone levels. 
            TSH levels are sensitive to excess or deficiency in circulating thyroid 
hormone levels.TSH levels are used for screening thyroid disorders.TSH levels 
are altered in acute illness, central hypothyroidism, presence of heterophile   
antibody and TSH auto antibody. In the presence of these antibodies, TSH will 
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be falsely elevated. In central hypothyroidism, decreased sialylation of TSH 
results in longer half life and reduction in bioactivity. 
        
Thyroid function abnormalities: 
 HYPERTHYROIDISM: 
 2-3% of females presenting with subfertility  present with 
hypo/oligomenorrhoea, increased sensitivity to GnRH  and have increased 
LH,SHBG and total estrogen levels, but they remain ovulatory. 
            There is no evidence to support that treatment of clinical/sub clinical 
hyperthyroidism improves ovulation. Radioactive Iodine is used in the treat-
ment of Grave’s disease. Postpone pregnancy for 6 months after treatment. 
Signs of Hyperthyroidism: 
• Unexplained weight loss, increased appetite 
• Anxiety, panic attacks, and heart palpitations 
• Feeling hot, sweating, and having an intolerance to heat 
• Diarrhea 
• Amenorrhea (not menstruating) or short menstrual cycles (<26 
days) 
• High BBTs (>36.7°C before ovulation, >37.2°C after ovulation) 
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HYPOTHYROIDISM: 
Prevalence of hypothyroidism in reproductive age group females is 2-
4%(Wang C, Crapo L.M., 1997),(Bjoro T.,Holman J.,Kruger O.,2000) 
Autoimmune thyroid disorders are the most common cause of hypothyroid-
ism.(Vanderpump M.P., Turnbridge W.M., French.J.M., 1995) 
Overt Hypothyroidism-0.5% of reproductive age group 
Subclinical Hypothyroidism- 2-4% of reproductive age group. 
Subclinical Hypothyroidism is defined as raised S.TSH>4.5mIU/L with normal 
T4 and no clinical symptoms or signs of hypothyroidism. 
How does hypothyroidism cause Infertility? 
           Hypothyroidism affects pulsatile release of GnRH, cyclical release of 
FSH and LH, thereby causing impairment in ovulation. It presents as            
oligomenorrhoea /menorrhagia /amenorrhoea. 
 Increased S.TSH level may cause anovulatory cycle and menstrual distur-
bances and thereby decreasing the fertility rate( Krassas et al). 
In a study done by Joshi et al-menstrual abnormalities were noted in 68% of 22 
hypothyroid females.,where as 12% 1n 49 controls. 
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           Thyroid hormone receptors are expressed by ovarian granulosa 
cells,cumulus cells,oocytes and enables activation of  LH receptors and    
progesterone production,which is impaired in hypothyroidism. 
           Hypothyroidism alters pituitary feedback, changes estrogen metabolism 
and binding activity of circulating  SHBG. 
           Bals –Bratsch et al proved corpus luteal insufficiency in infertile       
patients with subclinical hypothyroidism. 
           Increased sensitivity of prolactin secreting cells to TRH and defective 
Dopamine turnover resulting in hyperprolactinemia, causing anovulatory      
infertility.  
            Grassi et al showed that mean duration of infertility was significantly 
longer in patients with thyroid disorders 
            Improvements in implantation/pregnancy/live birth rate achieved with 
Levothyroxine treatment in those with overt and subclinical cases, but still less 
when compared to euthyroid patients. 
 On the basis of this evidence, there is shift in practice to maintain S.TSH 
<2.5mIU/L in line with American Thyroid Association Guidelines. 
A study conducted by Lincoln et al showed elevated S.TSH in 2.3% of 
females without thyroid disease. 
  
35 
 
Arojokie et al studied the prevalence of elevated S.TSH in other causes 
of infertility. 
Ovarian dysfunction-6.3% 
Tubal Infertility-2.6% 
Idiopathic-4.8% 
Endometriosis-none. 
Potential Causes of  Hypothyroidism: 
Primary 
• Congenital absence of thyroid gland 
• External thyroid gland radiation 
• Familial disorders of thyroxine synthesis 
• Hashimotos thyroiditis 
• I-131 ablation for Graves disease 
• Ingestion of Antithyroid drugs 
• Iodine deficiency 
• Idiopathic Myxoedema 
• Surgical removal of thyroid gland 
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                     Secondary: 
• Hypothalamic thyrotropin releasing hormone deficiency 
• Pituitary or hypothalamic tumors or disease 
Signs of hypothyroidism: 
o Unexplained weight gain, lack of appetite, difficulty losing 
weight 
o Feeling cold, chills that are difficult to warm up from 
o Constipation 
o Long menstrual cycle (>32 days), heavy periods 
o Low BBTs (<35.6°C before ovulation, <36.0°C after ovula-
tion) 
o Dry skin 
o Fatigue, difficulty concentrating, brain fog 
o History of miscarriage 
o Swelling of the legs and ankles 
Immunological Abnormalities: 
AUTOIMMUNE THYROID DISORDER is the most common 
thyroid abnormality in females. It is the result of combined effects of multiple 
thyroid Abs. It may coexist with other autoimmune disorders/ Addissons/  Ova-
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rian failure/Sjogrens/ Rheumatoid Arthritis/ Type  I DM/ Vitiligo/ Pernicious 
Anaemia/ ITP/ Myasthenia Gravis. 
AITD is suggestive of lymphocytic infiltration and therefore pre-
dictive of thyroid disease. Subfertility also seen in euthyroid women with 
AITD. 
Gerhard et al showed 44% of females with AITD had            
endometriosis. 
Jannsen et al showed strong association between AITD and 
PCOS.    
Antithyroid Antibody is seen in ovarian follicular fluid of wom-
en.  Apparent   reduction in fertility include raised T Cell population within the 
endometrium, polyclonal B Cells cross reacting with trophoblastic placental 
tissue, Vitamin D deficiency/ NK cell hyperactivity, cross reacting with placen-
tal and zona      pellucida antibodies. 
Women with AITD and euthyroid status started on levothyroxine 
treatment had improved pregnancy outcomes. 
Thyroid Autoantigens- 
Thyroglobulin 
Thyroid Peroxidase 
  
38 
 
TSH Receptor 
Na/I Symporter 
Thyroid Autoantibodies- 
Antithyroglobulin Antibody 
Anti thyroid peroxidase Antibody 
AntiTSH Receptor Antibody 
Anti Na/I Symporter Antibody 
Breach in normal immune surveillance causes antibody production to 
thyroglobulin. 
Antithyroglobulin Antibody- 
              Non complement fixing,  polyclonal, IgG class 
Anti TPO Antibody- 
            Anti TPO Ab is cytotoxic, complement fixing IgG Ab. 
            Most sensitive of Autoimmune Thyroid Disorder 
  To assist in the diagnosis of autoimmune thyroiditis in euthyroid patients with 
goiter or nodule. 
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Used in conjunction with TSH to predict future hypothyroidism in sub-
clinical hypothyroid patients. 
AntiTSH Receptor Antibody 
TSH receptor is a GPCR. Abs are capable of activating or blocking TSH 
Receptor function. 
              Each Ab type correlates with severity of disease/extraglandular 
signs,risk of fetal effects and chances of remission and recurrence. 
AntiNIS Antibody: Experimental 
Screening for hypothyroidism 
American Association of Clinical Endocrinologists recommend screen-
ing women prior to conceiving or at the first prenatal appointment. They also    
recommend screening for presence of hypothyroidism in patients with Type I 
DM, patients on Lithium therapy, patients presenting with Infertility and      
Depression45,46. 
Endocrine Society’s Clinical Practice guidelines regarding    manage-
ment of thyroid dysfunction during pregnancy and post-partum recommends 
targeted screening for the following  individuals: 
         H/O Thyroid disorder 
         Family H/O Thyroid disease 
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         Goiter 
         Thyroid auto antibodies 
          Clinical signs and symptoms of thyroid disease 
          Autoimmune disorders 
          Infertility 
          Head and Neck Radiation 
Targeted screening may miss 30% of sub-clinical hypothyroidism. 
           According to these recommendations, preconceptionally diagnosed     
hypothyroid women should have their T4 adjusted such that TSH value< 
2.5mIU/L before pregnancy. T4 dosage for females already on thyroxine re-
quire dose escalation at 4-6 weeks gestation in order to maintain a TSH value 
<2.5 mIU/L47,48. 
          Euthyroid females with thyroid antibodies are at risk of hypothyroidism 
and should have TSH screening in each trimester. 
         Sub-clinical hypothyroidism is associated with adverse outcomes for 
mother and fetus, so T4 replacement is recommended. 
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THYROID FUNCTION TEST 
TSH Assay 
TSH assay measures the concentration of TSH in serum.TSH assay is 
classified by ‘generation’based on functional sensitivity of the assay. TSH is 
exquisitely sensitive indicator of thyroid status. Hence it is a frontline thyroid 
function test. 
 Normal Serum TSH level- 0.3 to 5 mIU/ml. 
TSH is under negative feedback control by the amount of free T4 and 
free T3 and positive control by TRH. 
TSH can be used effectively to monitor patients being treated with    
thyroid hormone. Results may be misleading during the period of equilibration. 
Hence T4 serves as frontline assay during this period. 
Total T4 and Free T4 assay 
       T4 assay complements TSH assay and is used to confirm a thyroid        
disorder, hence suggested by abnormal TSH levels. 
       Total T4 measures concentration of thyroxine in serum including both pro-
tein bound and free hormone. Any condition that affects TBG will alter Total 
T4. 
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      Free T4 assay measures biologically active fraction in serum- more reliable 
indicator of true thyroid status. 
Total T3 and Free T3 assay 
Total T3 is elevated earlier than Total T4. 
Total T3 is more sensitive indicator of hyperthyroidism than Total T4. 
T3 assay used for differential diagnosis of T3 thyrotoxicosis. Only free 
T3 is biologically active, accounts for 0.5% of Total T3- more reliable indicator 
of true thyroid status. 
MANAGEMENT 
Subclinical Hypothyroidism improves with levothyroxine                 
supplementation.  
Bhonet et al-11 out of 20 were treated with 50 microgram of              
levothyroxine of which 2/11 became pregnant. 
LEVOTHYROXINE 
Synthetic Thyroid hormone. 
Levothyroxine is a chiral compound in the L-form. 
Available Preparations: 
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       Oral Tablets 
  Intra muscular injections 
Intra venous infusions 
According to AACE and ATA, brand name and generic forms are not 
bio-equivalent as approved by FDA. 
TSH and T4 checked every 6 weeks for patients on treatment. 
          [Gaitonde Dy, Sweeney LB(August 2012)] 
Adverse Effects: 
          Once patients are stabilized on thyroxine treatment, annual or semi-
annual clinical evaluations and TSH monitoring are appropriate. 
 Long term TSH suppression causes cardiac side effects and osteoporo-
sis- Frilling A,LIUC, Weber F(2004) 
 Too high dosage may mimic hypothyroidism. 
 Massive overdose causes sympathetic overactivity, which requires Beta 
blockers therapy. 
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Interactions: 
            Calcium and iron decreases the absorption of levothyroxine- Ruth H, 
Michael, Neafsey(2004) 
Other  Substances interfering with thyroxine Absorption 
                Aluminium hydroxide 
                Cholestyramine 
                Iron,Calcium 
                Sucralfate 
Rifampin and Sertraline hydrochloride may accelerate the metabolism of 
levothyroxine. 
Dosage: 
Taken in empty stomach 30 minutes to 1 hour before meals. Recent 
study published in JAMA showed greater efficiency of  Levothyroxine when 
taken at bed time. 
         Dose: 1.6 microgram/kg body weight/day49 
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Mechanism of Action: 
       In the periphery T4 is converted into active metabolite T3. T3 binds to  
thyroid receptor proteins in the cell nucleus and cause metabolic effects 
through the control of DNA transcription and protein synthesis. 
Pharmaco-kinetics: 
      40 to 80% is absorbed from jejunum and upper ileum. Bioavailability is  
decreased by concomitant dietary fibre intake. 
Distribution: 
      99% in bound form. Only free form is metabolically active. 
Metabolism: 
     T4 de-iodination takes place in liver and kidney. 80% is    converted to T3. 
It also undergoes Entero Hepatic circulation. 
Elimination: 
    Half life of levothyroxine is 6-7 days for euthyroid patients, 9-10 days for 
hypothyroid patients and 3-4 for hyperthyroid patients. 
    Therfore nearly 6 weeks of treatment are necessary before the effects of    
dosage change can be evaluated. 
     80% of levothyroxine is excreted by kidneys. 
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Contra-Indications: 
9 Hypersensitivity to Levothyroxine sodium 
9 Acute MI 
9 Thyrotoxicosis 
9 Uncorrected Adrenal Insufficiency 
Management of hypothyroidism with hyperprolactinemia: 
        Hyperprolactinemia induced Luteal Phase Defects are associated with less 
severe forms of hypothyroidism. Replacement therapy with levothyroxine    
appears to reverse the hyperprolactinemia and corrects ovulatory defects50,51. 
Nutrition for Thyroid disorders 
Gluten-free diet: Gluten is the protein found in many grains, including 
wheat, spelt, rye, barley,etc. It may provoke inflammation in the gut wall,  
leading to a specialized immune reaction in the body. There is a high correla-
tion between untreated celiac disease (gluten allergy) and hypothyroidism9. 
This is due to cross reactivity between the immune response of gluten and   
thyroid gland, meaning the body accidentally attacks the thyroid gland with the 
immune proteins that are meant to attack gluten. Because of that thyroid is   
unable to function at optimal capacity, and features of autoimmune   thyroid 
disorder such as Hashimoto’s disease may manifest. To combat that gluten 
should be strictly removed from the diet. It takes about six months of being 
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completely gluten free in order to clear the immune response and stop the     
attack on the thyroid gland. 
Foods to avoid: Wheat, rye, barley, gliadin. Certain sauces and      
packaged goods may contain gluten. It is used as a filler and thickener in these 
foods. Those foods  should also be avoided. 
Foods to eat instead:  Brown rice, millet, amaranth, gluten-free oatmeal 
and buckwheat. 
Dairy-free diet:  Whey and casein proteins present in dairy foods can cause    
inflammation in the gut, which can lead to a body-wide immune response, 
causing whole body  inflammation. This can contribute to and worsen the 
symptoms of Hashimoto’s disease.  
• Foods to avoid: All cattle dairy products (milk, cheese, 
yoghurt, butter, etc.),foods containing casein or whey.  
• Foods to eat instead: Soy, coconut, rice milk products. 
• Lactose-free products may still contain the inflammatory 
proteins. So they should also be avoided unless labelled as “dairy-free”. 
 The Anti-Inflammatory Diet: For some persons with widespread                 
inflammation, indicated by high levels of anti-TPO and anti-TG, a more strict 
overall anti-inflammatory diet can be helpful for normalizing the thyroid    
function, as well as reducing overall inflammation in the body. It involves 
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eliminating all foods which are suspected to be a causative agent for              
inflammation and immune response in the body.  
Foods to avoid: Gluten, dairy, eggs, vegetables like tomato, potato,  all 
peppers including bell pepper and cayenne pepper, peanuts, red meat, refined 
sugar, artificial sweeteners, caffeinated beverages, processed foods. 
Foods to eat instead: Fish, chicken, soy, nuts, seeds, legumes, gluten 
free grains, dairy alternatives, honey, non-caffeinated teas. 
Other Supplements 
To address low thyroid function 
1. Selenomethionine – 200mcg per day. It  has got a role in lowering     
thyroid antibody levels 
2. Zinc picolinate – 30mg per day 
3. Iodine 100 mcg – 500mcg per day. Caution needed as very large iodine 
dose can increase thyroid antibodies. 
4. L-Tyrosine – up to 1000mg per day. This is an important nutrient for 
thyroid function. 
5. Herbal medicines include: Rhodiola, , Coleus, Bacopa, Ashwagandha. 
To address adrenal function as cause of hypothyroidism: 
        Nutrients to support the adrenal glands include: vitamin C, vitamin B5, 
vitamin B6, magnesium and many herbs. 
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Supplements to address inflammation (Hashimoto’s): 
1. Anti-inflammatory herbs : Boswelia (Boswellia serrata) and Tumeric 
(Curcuma longa).They have got powerful anti-inflammatory action. 
      2.Omega-3 fish oil: 1000-2000mg per day 
MISCELLANEOUS 
               1.Personal Habits 
                    Smoking increases the risk of infertility depending upon the 
amount and length of time a woman smokes. Smoking interferes with            
folliculogenesis, embryo transport, endometrial receptivity, endometrial       
angiogenesis. 
              2.Medical Conditions 
               Diabetes: It is associated with increased risk of infertility by means of 
causing  problems like delayed puberty/menarche, menstrual irregularities and 
early menopause. 
               Cancer: Gonadal dysfunction may occur as a result of certain        
cancers. Anti cancer drugs especially Alkylating agents and Radiation pose 
high risk of infertility.Cryopreservation of oocytes,embryos or ovarian tissue 
may be done to preserve fertility. 
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              3.EXERCISE 
                       Regular exercise – beneficial  
Excessive exercise  may lead to Luteal Phase Defect in the form of short luteal 
phase or poor endometrial maturation.This may be due to inadequate proges-
terone production.Strenuous exercise also may lead to habitual abortions. 
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OBSERVATION AND RESULTS 
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      Table 1.  Prevalence of infertility 
 
  
 
Hypothyroidism        49      30% 
Male Factor        24      16% 
Tubal Factor        20      14% 
PCOD        32      22% 
Endometriosis         6      4% 
Anomalies         3       2% 
Unexplained        16      12% 
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Table 2. Age vs Hypothyroidism 
 
Age in years Hypothyroidism Conception 
20 - 30  28 8 
31 - 40  17 4 
Total 45 12 
p value   8/28  &  4/17 0.956  Not significant   
   
This table shows distribution of hypothyroid infertile patients between two age 
groups of 20 -30 and 31 – 40 years. Conception rate in both the age groups   
following thyroxine treatment were compared. P value being 0.956 suggest age 
factor does not significantly affect the rate of conception in hypothyroidism. 
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 Table 3. BMI vs Hypothyroidism 
 
BMI Hypothyroidism Conception 
Normal (18.5 - 24.9) 13 5 
Overweight (25 - 29.9) 19 7 
Class I Obesity (30-34.9) 12 0 
Class II Obesity (35-39.9) 1 0 
Total 45 12 
p value 12/32 & 0/13 0.049 Significant   
                                                                                                                                        
 
  This table compares the conception rate among hypothyroid infertile patients 
belonging to different class of BMI. Conception rate was higher in patients   
belonging to normal and overweight class. P value being 0.049 suggests that 
BMI affects conception significantly. 
  
 
0
2
4
6
8
10
12
14
16
18
20
Normal (18.5 
24.9)
13
5
 
‐ Overwe
2
1
Diag
H
57
ight (25 ‐
9.9)
9
7
ram 3. BM
ypothyroidism
Class I Obesity
34.9)
12
0
I VS HYPOTH
Concepti
 (30‐ Class I
YROIDISM
on
I Obesity (35‐
39.9)
1
0
  
58 
 
Table 4.Clinical & Subclinical hypothyroidism 
  Hypothyroidism Conception 
TSH > 10, ↓ FT3/FT4 - Clinical 5 0 
TSH 2.5 – 10, Normal FT3/FT4- 
Subclinical 40 12 
Total 45 12 
p value  0/5  &  12/40 0.526  Not sig   
 
Table 4 compares conception rate among clinical and subclinical hypothyroid 
patients. Of the 40 subclinical hypothyroid patients 12 conceived with   
levothyroxine treatment whereas none out of 5 clinical hypothyroid patients 
conceived. 
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Table 5.Hypothyroidism and Serum prolactin 
 
Serum prolactin (ng/ml) Hypothyroidism Conception 
< 19.9 15 9 
20 - 24.9   22 3 
 > 25 8 0 
Total 45 12 
p value for 9/15, 3/22, 0/8  0.026  Significant   
Hypothyroid patients were categorized based on serum levels of prolactin    
during the first visit. Their response to levothyroxine treatment on follow-up 
was compared.P value being 0.026 suggests that patients with serum prolactin 
less than 25ng/ml responded better to treatment. 
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Table 6.Hypothyroidism and Anti TPO Abs 
 
Anti TPO (mIU/ml) Hypothyroidism Conception 
< 34 27 11 
 > 34   18 1 
Total 45 12 
p value for 11/27 & 1/18 0.045  Significant   
 
 Hypothyroid infertile patients were screened for anti TPO antibodies 
with cut off levels of 35mIU/L. Table shows that greater the anti TPO titre less 
is the chance of conception owing to auto immune thyroid disorder. This is   
reinforced by significant P value of 0.045. 
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Table 7.Hypothyroidism and Menstural irregularity 
 
  Hypothyroidism Conception 
Oligomenorrhoea 27 3 
Amenorrhoea 2 0 
Regular 16 9 
Total 45 12 
p value for 3/27, 0/2, 9/16 0.047  Significant   
 
  
 Hypothyroid infertile patients were grouped according to the pattern of 
menstrual cycle. Patients with regular cycles were found to conceive.           
Significant P value of 0.047 suggests pattern of menstrual cycle also affects 
conception. 
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Table 8.Hypothyroidism  and Endometrial sampling 
 
Endometrial  Hypothyroidism Conception 
Secretory EM 17 9 
Non Secretory EM 28 3 
Total 45 12 
p value for  9/17,  3/28 0.048 Significant 
 
Hypothyroid infertile patients were subjected to pre menstrual            
endometrial sampling and the conception rate was compared between two 
groups. Patients categorized based on histopathology as secretory EM and Non 
secretory EM. 
P value being 0.048 suggests patients with secretory phase endometrium 
had higher rates of conception. Secretory EM indicates ovulatory cycles. 
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Table 9.Hypothyroidism  and Altered LH / FSH 
 
  Hypothyroidism Conception 
FSH  >  10 2 0 
Reversed LH / FSH 9 1 
Normal 34 11 
Total 45 12
p value for  0/2,  1/9, 11/34 0.454  Not significant   
 
Day 2 LH / FSH screening done for all infertile patients. As per the table,     
hypothyroid infertile patients with normal LH /FSH were 34 and altered        
LH /FSH were 11. P value being 0.454 suggest conception is not affected by 
alteration in LH / FSH ratio. 
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Table 10.Hypothyroidism  and Period of Infertility 
 
Period of infertility in years Hypothyroidism Conception 
< 3  9 2 
 3 - 5    12 6 
  5 - 10   19 1 
> 10       5 3
Total 45 12 
p value 0.107  Not significant   
 
Table 10 shows comparison of conception among hypothyroid infertile 
patients based on period of infertility. P value being  0.107 suggest that the    
period of infertility does not influence the rate of conception in hypothyroid-
ism. 
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Table 11.Initial TSH level and Conception 
 
TSH - I visit MIU / L Hypothyroidism Conception 
2.5 - 6.5 25 11 
6.6 - 10   15 1 
>  10 5 0 
Total 45 12
      
<6.5   vs  > 6.5    
p value 11/25 & 1/15 0.040  Significnat 
 
 
Patients were categorized based on the serum TSH levels during first 
visit and conception rates were compared. P value being 0.040 suggests that 
lower the serum TSH level better the chance of conception.
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Table 12. On follow-up 
 
Duration of Treatment Conception Rate 
6 weeks  -  3 months 2 
3 months - 1 year 10 
Total 12 
  
 
     This table shows the conception rate following levothyroxine treatment over 
a period of time. 2 patients were found to conceive over 6 weeks to 3 months of 
therapy and 10 patients over 3 months to 1 year of therapy. 
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DISCUSSION 
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 Thyroid hormones have profound influence on reproduction and     
pregnancy. Thyroid dysfunction manifests as broad spectrum of reproductive 
disorders ranging from abnormal sexual development to menstrual                
irregularities and infertility. 
 Hypothyroidism causes elevated TRH production which stimulates    
pituitary to secrete TSH and prolactin. Hyperprolactinemia affects fertility    
potential by impairing GnRH pulsatility and thereby ovarian function. 
1. Prevalence of subclinical hypothyroidism (23.3% ) was more     
common than overt hypothyroism (3.3% ) and the results were      
consistent with Verma et al , Birader et al and Rijal et al  (2011). 
2. There was no significant difference in age among different groups 
and according to thyroid status ( P > 0.05 ). 
3. Conception rate was significantly influenced by BMI in patients with 
hypothyroidism (P < 0.05). the result was similar to Rahman et al. 
4. Higher TSH levels were associated with lower conception rate which 
was similar to that of Raber et al and Gerhard et al. 
5. Subclinical hypothyroid patient responded better to levothyroxine 
treatment, where as none of clinical hypothyroidism conceived. 
6. Lower the level of serum prolactin, better is the response to treatment. 
7. Higher titres of anti TPO antibodies have a negative impact on     
conception despite thyroxine treatment. 
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8. 64% of hypothyroid patients were found to have irregular cycles in 
par with the study conducted by Joshi et al-68%. Patients with    
regular cycles had better chance of conception. 
9. Secretory phase of endometrium in premenstrual endometrial      
sampling suggestive of ovulation favours conception in hypothyroid 
individuals. 
10. Period of infertility does not significantly affect conception in        
hypothyroid individuals.   
11. Study by Verma et al in 2012: 
         394 infertile women were investigated for S.TSH and 
S.Prolactin.  94 were found to be hypothyroid of which 72(76.6%) 
females conceived following levothyroxine treatment, wherein 45 
(62.5%) conceived after 6 weeks to 3 months of treatment and 27 
(37.5%) conceived following 3 months to 1 year of treatment.         
Infertile female with hyperprolactinemia also responded to treatment 
for hypothyroidism and conceived. 
12. Study by Nishat Akhtar and D.Mohanapriya at Jawaharlal Medical 
College Hospital, A.M.U. Aligarh: 
           Of 98 infertile female, 3 were excluded due to associated 
causes and of the 95, 51(53.7%) were hypothyroid and 44(46.3%) 
were euthyroid. 
 Of the 51, 48(50.5%) were subclinical hypothyroid and 3(3.2%) were 
overt hypothyroid.  
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Of the 48, 16(33.3%) conceived. 1(6.3%) within 6 months of     
treatment, 4(25%) within 6 months to 1 year and 11(68.7%) within   
1-2years of treatment. 
None among overt hypothyroidism conceived. 
13. In our study,                 
                 Of the 150 infertile women studied, 4 were excluded due 
to   associated ovarian factors/male factors/tubal factors. Of the      
remaining 146, 45 were hypothyroid(31%) and the remaining 101 
were euthyroid(69%). In that 45  hypothyroid   patients, 40 were   
subclinical(89%) and 5 were clinical(11%). Among the 40 subclinical 
hypothyroid patients, 12 conceived after thyroxine treatment(30%). 
Of the 12, two conceived within three months(17%) and the           
remaining ten within 1 year of thyroxine treatment(83%). 
Thyroid dysfunction is a common cause of infertility, which can be    
corrected by levothyroxine supplementation and bringing TSH to        
appropriate levels. In case of raised TSH with elevated serum prolactin, 
the treatment is first targeted to normalize thyroid level even before 
evaluating the cause of hyperprolactinemia. Levothyroxine treatment 
normalizes the menstrual cycle, prolactin levels and improve the fertility 
rates. Hence with simple oral treatment, 30% hypothyroid infertile       
patients conceived after 6 weeks to 1 year. TSH levels were maintained 
by adequate drug dosage and serial monitoring at 6-8 weeks interval. 
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 Therefore, normal TSH levels are a prerequisite for fertilization. Hence 
initiation of levothyroxine treatment in hypothyroid women is justified. 
Women in the group of serum TSH levels 2.5 – 6.5microIU/ml  with no 
clinical symptoms of hypothyroidism are not to be ignored and carefully 
managed so that they benefit a lot pertaining to fertility. Hence, screening 
for  serum TSH, serum prolactin are essential before adopting a battery of 
hormonal assays and costly invasive procedures. 
 For better management of infertility cases, we should plan further    
studies with large sample size and long term follow up, which are neces-
sary to validate the variations in serum TSH and prolactin levels. 
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SUMMARY 
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 Study was conducted in the Gynaecology Out Patient Department of 
Government RSRM Hospital (Stanley Medical College and Hospital), Chennai 
to identify the prevalence of hypothyroidism in infertility and assess the        
response to treatment. 
           150 primary infertile patients were selected for the study over a period 
of 1 year.  Infertile patients were screened for TSH and prolactin at first visit 
and thyroid function determined. Of which   49     patients were hypothyroid, 
45 patients had no other associated causes of   infertility. 40 were subclinical 
and 5 were clinical hypothyroid patients. 
 Hypothyroid patients were compared based on all confounding factors 
like age, BMI, Period of infertility, Initial TSH levels, Pattern of menstruation, 
Serum prolactin levels and anti TPO antibody titres, premenstrual endometrial  
histology. Accordingly the conception rate was also found to vary. Low BMI, 
low serum prolactin, low anti TPO  antibody titre, regular cycles, ovulatory cy-
cles, lower TSH levels favour conception significantly. 
 Age and period of infertility do not influence the rate of conception in 
hypothyroid patients. 
 Simple oral levothyroxine treatment to optimize serum TSH level less 
than 2.5mIU/L by serial monitoring at 6-8 weeks interval showed conception 
rate of 30% within a span of 1 year. 
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CONCLUSION 
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9 Subclinical hypothyroidism is a common cause of infertility 
which can be easily treated with oral levothyroxine supplemen-
tation, thereby optimizing TSH levels <2.5mIU/L. 
 
9 Hence, screening for serum TSH at initial infertility workup is of 
prime importance before subjecting the patients to a panel of 
costly and invasive    investigatory modalities. 
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ANNEXURES 
 
 
Ma;thsh; : kU. jp. kQ;R  
    KJepiy gl;l Nkw;gbg;G khztp> 
   kfg;NgW kw;Wk; ngz;ikg; gpzpapay; gl;lg;gbg;G> 
   muR ];lhd;yp kUj;Jtkid> 
   nrd;id – 600 001 
 
topfhl;lp : Nguhrphpah; kU. tre;jhkzp 
   kfg;NgW kw;Wk; ngz;ikg; gpzpapay; Nguhrphpah;> 
   muR ];lhd;yp kUj;Jtkid> 
   nrd;id – 600 001 
 
    Ra xg;Gjy; gbtk; 
ngah;:      taJ:  cs;spUg;G vz;: 
 
 kyl;Lj;jd;ik cs;sth;fspy; vj;jid NgUf;F Neha;f;Fwp Njhd;wh ijuha;L Rug;gp 
Fiw cs;sJ vd;gJ gw;wpAk;> mg;gb ghjpg;G cs;sth;fSf;F ijnuhl;rpd; khj;jpiu %d;W 
khjq;fs; toq;fg;gl;L> mjd; tpisTfs; gw;wpAk; fz;lwptjw;fhf elj;jg;gLk; Ma;T ,J 
vd;gJ vdf;F tpsf;fg;gl;lJ. 
 ijnuhl;rpd; khj;jpiu vLj;Jf; nfhs;tjw;F KOkdJld; rk;kjpf;fpNwd;. 
 Vd;Dila re;Njfq;fisf; Nfl;fTk; mjw;fhd jFe;j tpsf;fq;fisg; ngwTk; 
tha;g;gspf;fg;gl;lJ. 
 ehd; Ma;tpypUe;J tpyfpf; nfhz;lhYk; Ma;thsh; vd;Dila kUj;Jt 
mwpf;iffisg; ghh;g;gjw;Nfh my;yJ cgNahfpf;fNth> vd; mDkjp Njitapy;iy 
vd;gijAk; mwpe;J nfhz;Nld;. Vd;id gw;wpa jfty;fs; ufrpakhf ghJfhf;fg;gLk; 
vd;gijAk; mwpNtd;. 
 ,e;j Ma;tpd; Kyk; fpilf;Fk; jfty;fisAk;> ghpNrhjid KbTfisAk; Ma;thsh; 
mth; jpUg;jpf;F Vw;g vt;tpjkhfTk; gad;gLj;jpf; nfhs;syhk;. mjid gpuRhpf;fTk; KO 
kdJld; rk;kjpf;fpNwd;. 
 ,e;j Ma;tpy; gq;F nfhs;s xg;Gf; nfhs;fpNwd; vdf;F nfhLf;fg;gl;l 
mwpTiufspd;gb ele;J nfhs;tJld; Ma;thsUf;F cz;ikAld; ,Ug;Ngd; vd;Wk; 
cWjpaspf;fpd;Nwd;. Vd; cly; eyk; ghjpf;fg;gl;lhNyh my;yJ tof;fj;jpw;F khwhd 
Neha;f;Fwp njd;gl;lhNyh clNd mjid njhptpg;Ngd; vd cWjp mspf;fpd;Nwd;. 
 ,e;j Ma;tpy; vdf;F vt;tpjkhd ghpNrhjidfisAk; Nkw;nfhs;s ehd; KOkdJld; 
rk;kjpf;fpd;Nwd;. 
 
 
Ma;thsh; ifnahg;gk;       Nehahspapd; ifnahg;gk;  
                                       PROFORMA         
                                                                                                                          DATE: 
NAME:                                                                              AGE:                       LMP: 
 IP NO:                                                                                                               
D.O.A:                                                     D.O.D                                                
ADDRESS & CONTACT NO: 
 
PRESENTING  COMPLAINTS:                                                                                                             
 
MENSTRUAL HISTORY:   
MARITAL HISTORY:                                                                                            
COITAL HISTORY: 
GYNAECOLOGICAL HISTORY: 
ANDROLOGICAL HISTORY: 
PAST HISTORY: 
PERSONAL HISTORY:     
FAMILY HISTORY: 
GENERAL EXAMINATION: 
HT:                                  WT:                            BMI:                                    W/H ratio: 
HIRSUTISM:                  BREAST:                   THYROID:                    PUBIC AND AXILLARY HAIR:        
  TEMP:                          PR:                             BP: 
PALLOR:                                            PEDAL EDEMA: 
CVS:                                                   RS: 
P/A:                                                     P/S:                                         P/V: 
                                                                  
INVESTIGATIONS 
SEMEN ANALYSIS: 
GENERAL CAUSES: 
HB:                              TC/DC:                                   Platelet count:      
 RBS:                           Blood urea:                          Serum creatinine: 
Liver Function Test:                                                 Ultrasound pelvis: 
Chest X Ray:                                 Mantaux:                             ECG: 
Thyroid Function Test: 
                                                  Baseline                                              Follow up  
                                                                                          First visit                               Second visit  
Free T3 
Free T4 
TSH 
Serum prolactin : 
TESTS FOR OVULATION:  Premenstrual  Endometrial Sampling 
TUBAL PATENCY:              HSG: 
                                            Laprascopic Chromotubation: 
Anti TPO Antibodies in Hypothyroid female: 
   
TREATMENT: 
 
 
 
 
OUTCOME: 
 
 
T 
F.T3 
(pg/ml)
F
F.T4
(ng/dl)
T
TSH
(mIU/L)
S.PRL
(ng/ml)
T 
F.T3 
(pg/ml)
F
F.T4
(ng/dl)
T
TSH
(mIU/L)
S.PRL
(ng/ml)
T 
F.T3 
(pg/ml)
F
F.T4
(ng/dl)
T
TSH
(mIU/L)
S.PRL
(ng/ml)
1 Maheshwari 33502
Clinical 
hypothyroidism
4.2 1.9 35 18.8 52 Secretory 100 3.8 1.9 20 16.4 100 2.9 1.2 5.9 15 Negative
2 Rekha 34750
Subclinical 
hypothyroidism
3.3 1.3 9 17.6 22 Secretory 50 3 1.1 6 11.8 50 2.6 0.9 2.4 8.6 Positive
3 Rajeshwari 36984
Subclinical 
hypothyroidism
2.8 1.1 4.2 21 32 Secretory 50 2.6 1 1.8 19 50 Positive
4 Saranaya 37006
Subclinical 
hypothyroidism
3.4 1.1 5.8 29.25 38 Non secretory 50 3.1 0.9 3 21 50 2.7 0.8 2.2 17.2 Negative
5 Dhanalakshmi 40648
Subclinical 
hypothyroidism
3.5 1.4 5.4 24.6 15 Non secretory 50 3.1 2.1 3.2 22.4 50 2.7 1.8 1.2 19.8 Positive
6 Nirmalatha 42112
Clinical 
hypothyroidism
3.8 1.9 21.6 26.5 48 Non secretory 100 3.2 2 5 18.6 100 2.4 1.8 1.5 15.4 Negative
7 Malarvizhi 43341
Subclinical 
hypothyroidism
3.1 1.4 4.8 22.8 30 Non secretory 50 3 1.3 3.3 20 50 2.8 1.2 2.4 16.5 Negative
8 Kavitha 46285
Subclinical 
hypothyroidism
3.8 1.7 5.2 6.5 29 Secretory 50 3.4 1.9 3.75 7.2 50 2.8 0.9 1.8 7.1 Positive
9 Stella 47752
Clinical 
hypothyroidism
4.1 2.2 12 27.6 38 Non secretory 100 3.8 1.8 5.4 23 100 3.6 1.4 2.3 22.8 Negative
10 Umamaheshwari 50123
Subclinical 
hypothyroidism
2.6 0.8 5.3 22.3 32 Non secretory 50 2.5 0.9 4.1 15.6 50 2.3 1 2.2 12.2 Negative
11 Vadivukarasi 52635
Subclinical 
hypothyroidism
3.5 1.4 8.2 12.28 31 Secretory 50 3.2 1.2 5.4 12 50 2.9 1.1 2.9 12.1 Negative
12 Saradha 56019
Subclinical 
hypothyroidism
2.7 1.6 6.5 9.8 26 Secretory 50 2.5 1.4 3.8 10.2 50 2.3 1.2 2.2 9.6 Positive
13 Dhavabhavani 56482
Clinical 
hypothyroidism
2 0.7 15.2 26.2 54 Non secretory 100 2.1 1 9.4 24.8 100 2.3 1.2 5.2 21.2 Negative
14 Nithya 57369
Subclinical 
hypothyroidism
2.96 1.18 4.32 19.8 24 Secretory 50 1 1.2 2.1 18.3 50 Positive
15 Jafeera Banu 57654
Subclinical 
hypothyroidism
2.8 0.9 3.1 17.6 26 Non secretory 50 2.7 1.2 2.6 15 50 2.6 1.8 1.8 11.3 Negative
16 Sengamma 59432
Subclinical 
hypothyroidism
3.2 2.1 4.9 24.4 35 Non secretory 50 3 1.8 2.4 16.2 50 2.6 0.9 1.9 13.1 Positive
17 Jothi 70219
Subclinical 
hypothyroidism
2.8 1.6 6.4 18.4 29 Non secretory 50 2.9 1.8 3.2 15.1 50 2.3 1.5 2.1 14.8 Negative
18 Selvi 71005
Subclinical 
hypothyroidism
2.5 1.2 4.5 22.6 36 Non secretory 50 2.4 1.4 3.2 15.2 50 2.3 1.5 2.3 12.2 Negative
19 Logeshwari 77664
Clinical 
hypothyroidism
3.5 1.4 16 24.6 35 Non secretory 100 3.1 2.1 9.2 21.2 100 2.8 1.2 5.4 18 Negative
20 Pankajam 78561
Subclinical 
hypothyroidism
4.5 1.6 9.4 23.1 12 Non secretory 50 4.2 1.4 5 20.8 50 4.2 1.2 2.7 17.6 Negative
21 Amsaveni 84993
Subclinical 
hypothyroidism
3.1 1.2 9.4 24.8 35 Non secretory 50 2.8 1.1 6.5 22.2 50 2.4 1.5 2.8 21.4 Negative
22 Jhansi 88487
Subclinical 
hypothyroidism
2.9 1.2 6.8 23.4 31 Secretory 50 2.7 1.1 4.5 16.4 50 2.5 1 2.1 14.5 Negative
23 Srividhya 90147
Subclinical 
hypothyroidism
3.1 1.8 7.2 19.2 32 Non secretory 50 3.2 1.6 4.4 18.4 50 2.8 1.6 2.4 17.4 Positive
24 Gayatri 1014
Subclinical 
hypothyroidism
2.9 1.6 5.2 21.8 39 Non secretory 50 2.6 1.7 3.5 16.1 50 2.5 1.8 2.2 13.8 Negative
25 Jamuna 2010
Subclinical 
hypothyroidism
3.4 2 5 23.4 36 Non secretory 50 3.2 1.8 3.5 21.2 50 3.1 1.7 2.4 20.6 Negative
26 Arulmozhi 3784
Subclinical 
hypothyroidism
2.2 1.2 7.2 22.1 32 Secretory 50 2.5 1.4 3.4 20.4 50 2.8 1.2 2.6 19.7 Negative
27 Sowmiya 6732
Subclinical 
hypothyroidism
3.4 0.9 7.5 16.4 29 Secretory 50 3.2 1.2 4.5 15.8 50 3.1 1.4 2.7 14.2 Negative
28 Shilpa 7082
Subclinical 
hypothyroidism
3.2 2 6.5 25.5 39 Non secretory 50 3.1 1.7 3.5 23.2 50 2.8 1.1 1.8 20.6 Negative
UPT
FIRST VISIT SECOND VISIT THIRD VISIT
S.No. NAME OP No. DIAGNOSIS
Anti TPO Ab
Miu/ml
PRE 
MENSTRUAL
ENDOMETRIAL
SAMPLING
THYROXINE
DOSE
THYROXINE
DOSE
29 Radhika 10126
Subclinical 
hypothyroidism
3.1 1.8 6.4 14.4 28 Secretory 50 2.8 1.4 4.3 12.2 50 2.3 0.8 2.4 11.8 Positive
30 Devipriya 10429
Subclinical 
hypothyroidism
3.6 1.9 8.4 26.1 38 Non secretory 50 3.2 1.2 5.8 24.2 50 2.8 1 2.8 22 Negative
31 Mythili 11623
Subclinical 
hypothyroidism
3.2 0.8 6.6 22.8 36 Non secretory 50 3.1 0.9 4 19.4 50 3 1.2 2.3 16.2 Negative
32 Mohanapriya 12077
Subclinical 
hypothyroidism
3.5 2 7.8 21.4 31 Non secretory 50 3.2 1.8 4.1 19.4 50 2.8 0.8 2.5 15.6 Negative
33 Lakshmi 12653
Subclinical 
hypothyroidism
4 1.9 9.6 23.4 29 Secretory 50 3.8 1.5 6.4 18.4 50 2.5 1.2 2.8 12.2 Negative
34 Krithika 14003
Subclinical 
hypothyroidism
2.7 0.9 4.4 26.4 31 Non secretory 50 2.6 0.7 3.1 21.3 50 2.3 0.8 2.2 18.4 Negative
35 Lavanaya 14132
Subclinical 
hypothyroidism
2.8 1.6 6.2 16.8 26 Secretory 50 2.5 1.8 3.5 12.6 50 2.4 1.2 2.1 9.8 Positive
36 Victoria 14454
Subclinical 
hypothyroidism
3.2 2 6.4 22.6 37 Non secretory 50 2.8 1.8 3.4 17.5 50 2.4 1.2 2.2 14.2 Negative
37 Shanthi 15233
Subclinical 
hypothyroidism
3.2 1.6 4.5 17.4 28 Non secretory 50 3.4 1.2 2.4 14.2 50 3 1.1 1.8 13.2 Positive
38 Lakshmidevi 15854
Subclinical 
hypothyroidism
1.8 0.6 9.2 27.2 36 Non secretory 50 2.3 0.9 7.4 22.1 50 2.6 1.2 3 18.7 Negative
39 Girija 15963
Subclinical 
hypothyroidism
3.2 1.8 5 20.8 38 Non secretory 50 3.1 1.6 3.4 16.8 50 3 1.2 2.2 13.4 Negative
40 Jayapriya 17435
Subclinical 
hypothyroidism
3.2 1.8 6.5 18.2 30 Secretory 50 3.1 1.5 4.2 13.6 50 3 0.8 2.2 11.4 Negative
41 Nandhini 17652
Subclinical 
hypothyroidism
3.4 2 5.8 15.6 27 Secretory 50 2.8 1.6 3.5 13.2 50 2.4 1.2 1.8 11.8 Negative
42 Monisha 18359
Subclinical 
hypothyroidism
2.6 1.1 5.8 23.4 32 Secretory 50 2.4 1 4.2 18.5 50 2.3 0.8 2.5 15.3 Negative
43 Shankari 18823
Subclinical 
hypothyroidism
2.8 1.2 4.5 24 35 Non secretory 50 2.5 1 3.3 21.2 50 2.4 0.8 2.4 19 Negative
44 Velankanni 19842
Subclinical 
hypothyroidism
3.5 1.5 6.5 16.2 26 Secretory 50 2.8 1.3 4.2 14.1 50 2.5 0.8 2.4 12.4 Positive
45 Vaishanavi 19999
Subclinical 
hypothyroidism
3.8 0.9 8.9 21.7 31 Non secretory 50 3.4 1.2 5.4 17.6 50 3.1 1.4 2.9 14.4 Negative
S.NO NAME OP NO. AGE
M/S
(yrs)
MENS.
HISTORY
Ht.
(cm.)
 Wt.
(kg.)
BMI W/H
CLINICAL
FEATURES
SEMEN
ANALYSIS
vol.(ml)/TC(milli
on)/Motility(%)
BASIC  
INV.
USG
PELVIS
DAY 2
LH/FSH
TUBAL
PATENCY
T.
F.T3
(pg/ml)
F.
F.T4
(ng/dl)
T.
TSH
(mIU/L)
S.PRL
(ng/ml)
DIAGNOSIS
1 Maheshwari 33502 33 6 RMP 151 60 26.6 0.8 Thyromegaly 2/60/80 Normal Normal 5.5/6 B/L spill + 4.2 1.9 35 18.8
Clinical 
hypothyroidism
2 Sarala 33701 20 4 RMP 160 68 26.5 0.7 Normal 3.1/10/20 Normal Normal 3.5/4.5 B/L spill + 3.1 1.2 2.3 23.5
Male factor 
infertility
3 Rekha 34750 26 10 RMP 155 62 25.8 0.75 Normal 2.5/88/40 Normal Normal 4.2/6.1 B/L spill + 3.8 1.3 9 17.6
Subclinical 
hypothyroidism
4 Muniammal 35800 28 5 RMP 154 83 33.5 0.8
Acne+class 1 
obesity
2.5/60/40 Normal
B/L 
PCOS
6.8/1 B/L spill + 2.8 0.9 1.7 11.2
Ovulatory 
dysfunction‐
PCOD
5 Samundeshwari 36817 22 3.5 Ireg. 145 68 32 0.9
Class 1 
Obesity
2/90/45 Normal
B/L 
PCOS
7.1/5.2 B/L spill + 3.4 1.6 1.95 23.75
Ovulatory 
dysfunction‐
PCOD
6 Rajeshwari 36984 22 2 RMP 152 58 25 0.68 Normal 2/75/80 Normal Normal 7.1/8.2 B/L spill + 2.8 1.1 4.2 21
Subclinical 
hypothyroidism
7 Saranya 37006 28 2 Amenorrhoea 146 50 23.4 0.7 Galactorrhoea  2.5/70/60 Normal Normal 8.2/11.5 B/L spill + 3.4 1.1 5.8 29.25
Subclinical 
hypothyroidism
8 Dhanalakshmi 37104 30 2 Oligomenorrhoea 148 56 25.5 0.6 RV uterus 3/25/45 Normal Normal 4.5/7.4
D‐Lap: Lt 
Hydrosalphinx/Abs
ent Lt spill
2.6 1.3 1.3 10.6 Tubal block
9 Hajira 39219 30 1 RMP 154 59 25 0.7 Normal 1.5/10/30 Normal Normal 6.1/7.2 B/L spill + 2.8 1.2 2.5 10.4
Male factor 
infertility
10 Jayanti 39565 30 6 RMP 143 50 24 0.6 Normal 4/80/80 Normal Normal 7.1/8.8
D‐LAP:Rt spill + Lt 
not visualised 
4*5cm 
endometriotic cyst 
Adhesionlysis done
3.2 1.7 1.4 12.6 Endometriosis
11 kalpana 39613 20 1 Ireg 155 51 21 0.5 Normal 3/90/60 Normal Normal 6.8/7.5
Rt. Cornual block 
Lt. spill +
2.6 1.9 2.3 17.4 Tubal factor
12 Dhanalakshmi 40648 37 10 Oligomenorrhoea 160 58 22.6 0.6 Normal 4/30/50 Normal Normal 6.8./8.4 B/L spill + 3.5 0.5 5.4 24.6
Subclinical 
hypothyroidism
13 Satyakala 40789 32 13 RMP 160 70 27 0.7 Normal 1.5/45/40 Normal Normal 7.8/8.4
severe cervical 
stenosis + B/L 
unhealthy 
tubes&fimbria
3.2 1.8 2.4 10.46
Anatomical 
factors
14 Sandhya 40932 21 3 RMP 152 66 28.5 0.8
Acne+overwei
ght
2/88/55 Normal
B/L 
PCOS 
8.5/9.2 B/L spill + 3.1 1.4 1.6 24.6
Ovulatory 
dysfunction‐
PCOD
15 Aishwarya 41110 22 4 RMP 159 65 25 0.7 Normal 1/68/65 Normal Normal 7.8/9.2 B/L spill + 2.5 1.5 1.7 15.5 Unexplained
16 Reeta 41623 26 10 RMP 166 74 27 0.6 Normal 2.5/63/70 Normal Normal 6.8/8.6 B/L spill + 3 1.4 1 14.2 Unexplained
17 Nirmalatha 42112 28 7 Oligomenorrhoea 154 84 35.41 0.7
Class 2 
obesity
4/80/60 Normal Normal 11.7/3.9 B/L spill + 3.8 1.9 21 26.5
Clinical 
hypothyroidism
18 Shameem 42785 24 1.5 Ireg 152 88 38 0.9 class 2 obesity 2/95/80 Normal
B/L 
PCOS 
8.4/8.1 B/L spill + 2.8 1.1 1.4 22.8
Ovulatory 
dysfunction‐
PCOD
19 Suseela 43125 35 13 RMP 150 62 27 0.7 Normal 2.5/75/80 Normal Normal 6.8/8.6
D‐LAP Rt. Proximal 
tubal block Lt 
isthmus block
2.6 1.4 1.9 14.6 Tubal factor
20 Malarvizhi 43341 35 4 RMP 151 60 26 0.7 Normal 1.5/60/55 Normal Normal 5.8/8.2 B/L spill + 3.1 1.4 4.8 22.8
Subclinical 
hypothyroidism
21 Satya 43861 22 2 Ireg 156 54 22 0.6 Normal 3.5/95/54 Normal
B/L 
PCOS 
6/6.5 B/L spill + 2.6 1.4 1.8 17.2
Ovulatory 
dysfunction‐
PCOD
22 Archana 44098 24 4 Ireg 150 56 25 0.7 Normal 2/97/70 Normal Normal 8.5/9
D‐Lap: B/L 
Hydrosalphinx/B/L 
spill‐
3.1 1.8 1.7 15.6 Tubal factor
23 Anitha 44154 28 1 Ireg 152 48 20 0.5 Normal 2,5/80/50 Normal
Small 
sized 
uterus
6.5/13
B/L spill + B/L 
hypoplastic ovaries
3.1 1.2 2 8.4 Uterine anomaly
24 Saira 44489 30 10 Oligomenorrhoea 148 60 27 0.7 Normal 2.5/80/40 Normal
B/L 
PCOS
7.8/7.5 B/L spill + 2.5 0.3 1.4 19.2
Ovulatory 
dysfunction‐
PCOD
25 Kala 46231 24 6 RMP 166 62 22 0.4 Acne 1.5/12/50 Normal
B/L 
PCOS
10.5/12 B/L spill + 2.6 0.9 1.9 8.4
Male 
infertility+ovulat
ory dysfunction‐
PCOD
26 Kavitha 46285 33 4 RMP 154 58 24 0.6 Normal 2.4/108/80 Normal Normal 5.5/7.8 B/L spill + 3.8 1.7 5.2 6.5
Subclinical 
hypothyroidism
27 Archana 47563 23 5 Ireg. 156 60 24.6 0.6 Normal 4/68/50 Normal
B/L 
PCOS
10.5/8.5 B/L spill + 2.7 1.5 1.6 22.6
Ovulatory 
dysfunction‐
PCOD
28 Stella 47752 34 8 Amenorrhoea 160 60 23 0.5
Galactorrhoea
+RV uterus
2.5/67/50 Normal Normal 16.2/5.4 B/L spill + 4.1 2.2 11.5 27.6
Clinical 
hypothyroidism
29 Suganaya 48123 23 3 RMP 156 52 21 0.6 Normal 3/95/75 Normal Normal 7.4/9.2  B/L spill + 2.6 1.2 2.5 16.5 Unexplained
30 Devi 48656 34 4 RMP 162 65 24.7 0.7 RV uterus 3/76/60 Normal Normal 4.5/5.9
D‐LAP Rt. Spill ‐e/o 
endometriosis + Lt. 
spill +
1.8 1 1.9 23.28 Endometriosis
31 Geetha 50062 28 2.5 RMP 148 60 27 0.76 Normal 3/38/40 Normal Normal 2.6/5.8 B/L spill + 2.5 0.9 1.46 18.51
Tubal 
block+ovulatory 
dysfunction‐
PCOD
32 Uma Maheshawari 50123 23 6 Oligomenorrhoea 150 73 32 0.88
Class 1 
obesity
3.5/52/80 Normal
B/L 
PCOS
6.2/5.4
HSG‐Lt spill + Rt 
spill + D‐LAP Both 
spill +
2.3 0.8 5.33 22.3
Subclinical 
hypothyroidism
33 Mumtaz 50236 20 2 RMP 154 62 26 0.72 Normal 1/17/15 Normal Normal 8.5/10.9 HSG‐B/L spill + 3.06 1.28 1.97 20.6 Male infertility
34 Saranaya 51365 24 3 RMP 154 50 21.08 0.56 Normal 1.5/72/65 Normal
Cervical 
TB 
lymphad
enitis 
treated
3.8/5.4
D‐Lap: B/L 
Hydrosalphinx/B/L 
spill‐
2.4 1.5 1.48 13.78 Tubal block
35 Nathiya 51865 26 2.5 Ireg. 148 62 28.3 0.72 Normal 2.5/63.5/55 Normal Normal 8.2/6.5
D‐LAP spill + B/L 
PCOS
2.6 1.7 2.5 11.16
Ovulatory 
dysfunction‐
PCOD
36 Vadivukarasi 52635 31 6 RMP 149 60 27.02 0.68 RV uterus 2/35/70 Normal Normal 5.4/6.8 B/L spill + 3.5 1.4 8.2 12.28
Subclinical 
hypothyroidism
37 Meenatchi 52845 36 7 RMP 154 58 24.45 0.7 Normal 3/80/40 Normal
8*10 cm 
Fundal 
fibroid 
blocking 
cornua
6.5/8.6
HSG Lt spill +   Rt 
spill ‐               
3.5 1.4 1.8 10.6
Tubal block 
cornual fibroid
38 Sudha 54154 29 8 RMP 152 60 25.06 0.7 Normal 1.5/10/32 Normal Normal 2.3/8.2 HSG B/L spill + 3.18 1.4 1.46 6.6 Male infertility
39 Usha 55236 25 4 Irregular 154 58 24 0.7 Normal 1/8.9/15 Normal
B/L 
PCOS
6.08/6.1
HSG Lt cornual 
block D‐LAP B/L 
spill +
2.6 0.9 1.54 22.32
Male 
infertility+ovulat
ory dysfunction‐
PCOD
40 Hemalatha 55785 29 2 RMP 156 62 24 0.8 Normal 3.5/61.5/75 Normal Normal 6.8/8.5
D‐LAP Lt spill + Rt 
hydrosalphinx spill ‐
Rt ovary PCOS
3.48 1.5 2.67 18.2
Tubal 
Factor+ovulator
y dysfunction‐
PCOD
41 Saradha 56019 28 2 RMP 152 60 24 0.72 Normal 2/95/55 Normal Normal 6.2/7.4 HSG B/L spill + 2.7 1.6 6.5 9.8
Subclinical 
hypothyroidism
42 Dhavabhavani 56482 24 6 Oligomenorrhoea 158 62 24.83 0.62
Buddchiari 
syndrome AI 
hepatitis
2.1/108/40 Normal Normal 6.8/7.5 HSG B/L spill + 2 0.7 15.2 26.2
Clinical 
hypothyroidism
43 Nithya 57369 27 6 RMP 164 72 26 0.8 Normal 1.5/82/65 Normal Normal 5.2/6.4 D‐LAP B/L spill + 2.96 1.18 4.32 19.8
Subclinical 
hypothyroidism
44 Jafeera Banu 57654 30 7 RMP 152 74 32 0.7
Class 1 
obesity
2.5/58/60 Normal Normal 5.4/8.6 D‐LAP B/L spill + 2.87 0.9 3.19 17.6
Subclinical 
hypothyroidism
45 Latha 58483 28 3.5 RMP 150 60 26.6 0.7 Hirsutism+ 2.5/65/65 Normal
B/L 
PCOS
11.5/10.2 B/L spill + 2.93 0.8 4.4 24
Subclinical 
hypothyroidism+
ovulatory 
dysfunction‐
PCOS
46 Nagalakshmi 58726 28 5 RMP 146 54 24 0.7 Normal 2/80/85 Normal Normal 8.6/9.4 D‐LAP B/L spill + 3.2 1.8 2.5 25.5 Unexplained
47 Sasikala 58863 24 4 Ireg. 158 58 23 0.69 Normal 2.5/102/70 Normal
B/L 
PCOS
8.2/8.4 D‐LAP B/L spill + 2.5 1.5 1.83 9.8
ovulatory 
dysfunction‐
PCOD
48 Sengamma 59432 30 10 Oligomenorrhoea 156 62 26.4 0.68 Normal 1.5/65/10 Normal Normal 8.5/9.2 HSG B/L spill + 3.2 2.1 4.92 24.4
Subclinical 
hypothyroidism
49 Sangeetha 60212 33 8 RMP 158 58 23 0.7 Normal 2.5/38/60 Normal
Uterus 
bulky
8.6/9.3
HSG B/L spill + D‐
LAP Ut bulky Rt 
spill + Lt fimbrial 
block
3.13 1.03 2.57 8.6 Tubal factor
50 Kannika 60581 21 3 RMP 155 49 20 0.5 Normal 1.1/10/15 Normal Normal 8.8/9.4 HSG B/L spill + 3 1.6 2.5 9.2 male infertility
51 Jothi 70219 22 4 Oligomenorrhoea 158 60 24 0.7 Normal 3.5/90/40 Normal Normal 13.8/4.6 HSG B/L spill + 2.8 1.6 6.4 18.4
Subclinical 
hypothyroidism
52 Sangeetha 70342 27 13 Ireg. 161 58 22 0.68 Normal 2.5/86/50 Normal
B/L 
PCOS
7.4/9.6 HSG B/L spill + 6.9 1 1.8 14.2
ovulatory 
dysfunction‐
PCOD
53 Selvi 71005 26 4 Oligomenorrhoea 158 65 26 0.75 Normal 3/48/40 Normal Normal 7.2/6.6 HSG B/L spill + 2.57 1.23 4.5 22.6
Subclinical 
hypothyroidism
54 Kalpana 71678 32 5 Ireg. 146 70 32 0.91
Class 1 
obesity,acne,h
irsutism,acant
hosis 
nigricans
3.5/98/60 Normal
B/L 
PCOS
11/8.2 HSG B/L spill + 2.04 1.57 2 21.2
ovulatory 
dysfunction‐
PCOD
55 Eswari 72589 28 3 RMP 152 60 24.9 0.8 Normal 3/85/50 Normal Normal 5.4/8.6
HSG Rt spill + Lt 
spill ‐ D‐LAP Rt 
spill + Lt spill ‐ 
fimbrial block +
2.3 1.5 2.5 5.6 Tubal block
56 Sathya 73625 30 5 RMP 157 54 21.9 0.52 Normal 1.5/10/10 Normal Normal 5/6.2 B/L spill + 4.2 1.2 1.7 9.2 male infertility
57 Malini 74623 28 6 Ireg. 142 65 32 0.94
Class 1 
obesity,hirsuti
sm
2.5/70/40 Normal
B/L 
PCOS
9.2/8.5 B/L spill + 3.2 1.4 2.4 11.1
ovulatory 
dysfunction‐
PCOD
58 Priya 75897 23 2 RMP 160 61 23.82 0.62 Normal 3/105/50 Normal Normal 5.2/6.5 D‐LAP B/L spill + 4.1 1.2 2.5 6.8 Unexplained
59 Devi 77234 34 10 Ireg. 158 62 24 0.78 Normal 3/70/40 Normal Normal 3.6/5.4
D‐LAP Rt 
hydrosalphinx spill ‐
Lt spill + 
4.2 0.9 2.4 12.2 Tubal factor
60 Logeswari 77664 28 4 Oligomenorrhoea 150 70 31 0.89
RV Uterus 
Class1 obesity
2.5/85/40 Normal Normal 7.8/9.2 HSG B/L spill + 3.5 1.4 15 24.6
Clinical 
hypothyroidism
61 Pankajam 78561 29 6 Oligomenorrhoea 152 62 26 0.68 Normal 4/60/50 Normal Normal 4.4/6.5 D‐LAP B/L spill + 4.5 1.6 9.4 23.1
Subclinical 
hypothyroidism
62 Sivashakthi 80233 30 6 RMP 158 57 22.83 0.63 Normal 2//66/60 Normal Normal 7.5/8.6 HSG B/L spill + 2.9 1.1 2.5 25.2 Unexplained
63 Keerthana 81256 28 3 RMP 162 58 22 0.58 Normal 3.5/76/70 Normal Normal 8.4/9.2 HSG B/L spill + 3 1.8 2.3 6.8 Unexplained
64 Kalyani 84751 32 3 RMP 161 60 23 0.58 Normal 1.5/10/10 Normal Normal 7.4/9.2 HSG B/L spill + 2.9 1.2 2 7.4 male infertility
65 Amsaveni 84993 31 6 Oligomenorrhoea 157 75 32.89 0.95
Class 1 
obesity
3/35/60 Normal Normal 6/7.2 B/L spill + 3.1 1.2 9.4 24.8
Subclinical 
hypothyroidism
66 Parameshwari 87072 28 5 Ireg. 152 65 28 0.78 Normal 2/40/60 Normal
B/L 
PCOS
4.2/5.4 HSG B/L spill + 2.7 0.9 2.4 11.2
ovulatory 
dysfunction‐
PCOD
67 Jhansi 88487 29 2 RMP 148 60 27 0.66 Normal 2.4/70/60 Normal Normal 7.4/9.1 HSG B/L spill + 2.9 1.2 6.8 23.4
Subclinical 
hypothyroidism
68 Srividhya 90147 30 4 RMP 162 70 26 0.62 Normal 4/70/80 Normal Normal 15.6/5.2 HSG B/L spill + 3.1 1.8 7.2 19.2
Subclinical 
hypothyroidism
69 Priyanka 23 27 2 RMP 157 61 24.79 0.61 Normal 2/15/10 Normal Normal 3.8/4.2 HSG B/L spill + 2.8 1.6 2.1 7.4 male infertility
70 Thenmozhi 421 29 6 Ireg. 158 61 24.43 0.69 Normal 4.5/80/70 Normal Normal 5.4/6.8 D‐LAP B/L spill + 3.4 0.8 1.2 6.8 Unexplained
71 Janaki 946 25 2 RMP 160 58 22.65 0.58 Normal 1.3/11/40 Normal Normal 6.1/8.2 HSG B/L spill + 3.1 0.8 1.6 5.2 male infertility
72 Gayatri 1014 28 6 Oligomenorrhoea 154 65 27.4 0.6 Normal 2.5/80/60 Normal Normal 7.8/9.1 HSG B/L spill + 2.9 1.6 5.2 21.8
Subclinical 
hypothyroidism
73 Chitra 1235 29 6 RMP 152 63 27.26 0.68
Hirsutism+Ac
ne
3/90/65 Normal
B/L 
PCOS
7.2/6.1 HSG B/L spill + 3.3 0.9 5.1 27.2
Subclinical 
hypothyroidism+
ovulatory 
dysfunction‐
PCOD
74 Jothi 1367 30 3 RMP 156 58 23.83 0.6 Normal 3.5/10/30 Normal Normal 6.8/8.1 HSG B/L spill + 3.2 1 1.8 9.2 male infertility
75 Lavanaya 1561 34 4 RMP 162 54 20.57 0.62
Difficulty in 
micturition,fib
toid at 
anterior lip of 
cervix
3.5/90/80 Normal
Ut 
14.4*8.5*
5.8
5.4/6.8
D‐LAP spill ‐ 8*6cm 
cervical fibroid 
abutting the 
bladder
2.9 1.8 2.4 6.8 Cervical fibroid
76 Esther 1879 30 3 RMP 161 58 22.37 0.58 Normal 1.1/10/40 Normal Normal 6.8/8.5 HSG B/L spil + 3.5 1 1.8 10.2 male infertility
77 Sheela 1934 28 5 RMP 158 61 24.43 0.62 RV uterus 4/102/60 Normal Normal 4.2/5.4
HSG Lt spill + Rt 
spill ‐ D‐LAP Rt 
cornual fibroid spill 
‐ Lt spill +
3 1.2 2.2 11.4 Tubal block
78 Jamuna 2010 26 4 Oligomenorrhoea 150 68 30.2 0.79
Class 1 
obesity
3.5/98/65 Normal Normal 16.2/5.4 HSG B/L spill + 3.4 2 5 23.4
Subclinical 
hypothyroidism
79 Safreen  2117 30 5 RMP 160 56 21.87 0.72 Normal 2.5/75/70 Normal Normal 7.5/8.6 HSG B/L spill + 3.7 1.8 2.4 9.8 Unexplained
80 Pushpalatha 2485 31 6 RMP 162 58 22 0.72 Normal 2.5/92/75 Normal Normal 6.4/7.5 HSG B/L spill + 3.6 0.8 1.6 6.8 Unexplained
81 Durgadevi 2889 32 5 RMP 158 65 26 0.74 RV uterus 3/106/70 Normal
Rt ovary 
6*5 cm 
cyst
6.5/7.2
HSG Rt spill ‐  D‐
LAP: Rt 
endometriotic cyst, 
Rt peritubal 
adhesions scarring 
+, Lt spill+
3.1 0.9 1.9 8.4 Endometriosis
82 Preetham 3072 28 2 RMP 150 51 24 0.64 Normal 2.5/13/30 Normal Normal 8.2/8.4 HSG B/L spill + 3.4 1.6 2.1 7.2
Male 
infertility+ovulat
ory dysfunction‐
PCOD
83 Arulmozhi 3784 30 3 RMP 152 62 26.83 0.79 Normal 3/80/60 Normal Normal 5.2/6.8 B/L spill + 2.2 1.2 7.2 22.1
Subclinical 
hypothyroidism
84 Poornima 3943 32 5 Ireg. 160 68 26.56 0.75 Normal 3.5/90/50 Normal
B/L 
PCOS
7.2/6.8 D‐LAP B/L spill + 3.2 1.2 2.3 27.2
ovulatory 
dysfunction‐
PCOD
85 Datchayani 4023 35 3 RMP 148 51 23.28 0.72 Normal 2/15/20 Normal Normal 5.2/6.4 HSG B/L spill + 2.4 1.6 2.4 18.4 Male Infertility
86 Saraswathy 4562 28 2 Irregular 154 58 24.45 0.64 Normal 2.5/66/70 Normal
B/L 
PCOS
6.5/6.8 HSG B/L spill + 2.8 1 2.4 19.2
Male 
factor+ovulatory 
dysfunction‐
PCOD
87 Kalaiarasi 4918 30 5 RMP 146 54 25.3 0.82 Normal 3/92/68 Normal Normal 7.6/8.2
HSG Lt spill ‐ Rt 
spill+  D‐LAP B/L 
spill +
3 1.2 0.8 8.4 Tubal factor
88 Mohana 5009 28 2 RMP 160 60 23.43 0.78 Normal 4/84/70 Normal Normal 7.6/9.2
HSG cannula could 
not be introduced
3.4 0.4 1.8 6.5 Cercical stenosis
89 Hemalatha 5558 30 6 Ireg. 149 70 31.02 0.89
Class 1 
obesity
3.5/90/60 Normal
B/L 
PCOS
7.6/8.4 D‐LAP B/L spill + 2.7 2 2.3 10.4
ovulatory 
dysfunction‐
PCOD
90 Kalaivani 6032 28 3 RMP 142 54 26.78 0.7 Normal 2.5/65/50 Normal Normal 6.8/7.6 D‐LAP B/L spill + 2.8 1.2 2.5 15.4 Unexplained
91 Jeevitha 6481 30 2 RMP 140 50 25 0.69 Normal 1.5/10/10 Normal Normal 4.3/5.5 HSG B/L spill + 3.2 1.5 1.6 8.6 Male factor 
92 Sowmiya 6732 28 6 RMP 158 56 22.43 0.58 Normal 3/106/75 Normal Normal 4.1/6.2 HSG B/L spill + 3.4 0.9 7.5 16.4
Subclinical 
hypothyroidism
93 Thulasi 6921 30 3 RMP 146 51 24 0.62 Acne+ 1.5/15/20 Normal
B/L 
PCOS
7.1/6.5 D‐LAP B/L spill + 3.3 0.9 2.1 16.4
Male 
factor+ovulatory 
function‐PCOD
94 Shilpa 7082 27 4 Oligomenorrhoea 140 58 29.59 0.81 Normal 2.1/78/62 Normal Normal 14.6/4.8 HSG B/L spill + 3.6 2 6.5 25.5
Subclinical 
hypothyroidism
95 Swarnalatha 7729 34 8 RMP 158 50 20 0.64 Normal 4/104/80 Normal Normal 6.5/8.4
D‐LAP extensive 
peritubal 
adhesions + B/L 
spill ‐
3.4 0.9 1.8 8.4 Tubal factor
96 Arokiyamary 8169 34 3 RMP 160 59 23 0.62 Normal 1.5/12/35 Normal Normal 5.8/7.4 HSG B/L spill + 3.2 1.2 2.4 11.2 Male factor
97 Thaju Begum 8652 29 4 Ireg. 145 68 32 0.89
Class 1 
obesity
3/94/70 Normal
B/L 
PCOS
8.4/7.6 HSG B/L spill + 3.4 0.9 2.1 13.6
ovulatory 
dysfunction‐
PCOD
98 Sharmila 9028 26 2 Ireg. 144 50 24 0.74 Normal 2/30/10 Normal Normal 4.4/6.8 HSG B/L spill + 3.2 1.8 2.5 10.8 Male factor
99 Jayanthi 9927 25 3 RMP 148 52 23.73 0.71 Normal 3.1/8/15 Normal Normal 4.2/5.8 HSG B/L spill + 3.3 1.8 2 14.6 Male Factor
100 Vasantha 10058 30 6 RMP 160 58 22.65 0.69 Normal 4/96/80 Normal Normal 4.8/6.2
D‐LAP B/L 
hydrosalphinx,fimb
ria unhealthy
3.8 1.2 2.3 8.6 Tubal factor
101 Radhika 10126 26 4 RMP 162 54 21 0.7 Normal 4.5/60/50 Normal Normal 6.8/8.2 B/L spill + 3.1 1.8 6.5 14.1
Subclinical 
hypothyroidism
102 Jaya 10362 30 2 RMP 161 58 22.3 0.68 Normal 1.5/10/20 Normal Normal 5.4/6.4 B/L spill + 1.8 2.3 1.2 18.8 Male factor
103 Devipriya 10429 32 7 Oligomenorrhoea 148 69 31 0.81
Class 1 
obesity
4.5/60/50 Normal Normal 8.4/6.2 B/L spill + 3.6 1.9 8.4 26.1
Subclinical 
hypothyroidism
104 Keerthana 10794 28 5 Oligomenorrhoea 160 56 21.8 0.68 Normal 3.8/70/50 Normal Normal 5.8/6.4 B/L spill + 1.9 2.1 0.8 15.4 Unexplained
105 Sheela 11321 32 5 Ireg. 157 62 25.1 0.7 Mtx+ 3/25/60 Normal Normal 6.2/7.4
B/L spill ‐ , 
Hydrosalphinx
3.4 1.2 2.1 19.4 Tubal factor
106 Ranjanai 11532 29 8 Ireg. 148 66 30.1 0.84
Class 1 
obesity+RV 
uterus
3/35/50 Normal
B/L 
PCOS
8.6/7.4
D‐LAP:Peritubal 
adhesion 
+,Endometriotic 
cyst +
3.4 1.9 2 21.4
Endometriosis+o
vulatory 
dysfunction‐
PCOD
107 Mythili 11623 28 6 Oligomenorrhoea 152 65 28 0.78 Normal 4.5/60/70 Normal Normal 9.8/3.2 B/L spill + 3.2 0.8 6.6 22.8
Subclinical 
hypothyroidism
108 Monicka 11841 25 4 RMP 160 57 22 0.62 Normal 4.2/50/40 Normal Normal 6.4/7.2
HSG:Rt spill ‐ Lt 
spill +
2.3 1.2 1.8 18.4 Tubal factor
109 Vaishali 12005 35 3 Ireg. 158 64 25.63 0.7 Normal 1/20/15 Normal
B/L 
PCOS
7.2/8.4 B/L spill + 3.1 1.5 1.6 22.4
Male 
factor+ovulatory 
function‐PCOD
110 Mohanapriya 12077 31 6 Oligomenorrhoea 157 66 26.7 0.62 Normal 2.5/70/60 Normal Normal 10.5/3.5 B/L spill + 3.5 2 7.8 21.4
Subclinical 
hypothyroidism
111 Kalaiselvi 12314 26 5 RMP 160 58 22.65 0.68 Normal 1/15/10 Normal Normal 5.4/6.2 B/L spill + 2.1 1.8 2.3 15.6 Male factor
112 Vinodhini 12555 27 5 Ireg. 158 61 24.43 0.66 Normal 3.2/60/50 Normal
B/L 
PCOS
6.7/7.2 B/L spill + 2.6 1.1 2.1 18.4
ovulatory 
dysfunction‐
PCOD
113 Lakshmi 12653 25 2 RMP 161 86 33 0.82
Class 1 
obesity
3.6/45/50 Normal Normal 5.4/7.2 B/L spill + 4 1.9 9.6 23.4
Subclinical 
hypothyroidism
114 Jothipriya 12924 24 3 RMP 161 58 22 0.61 Normal 10/2/2020 Normal Normal 6.2/7.8 B/L spill + 2.1 1.5 2.4 15.2 Male factor
115 Thilagavathy 13059 28 6 Ireg. 146 61 28.6 0.8 Normal 3.5/50/40 Normal
B/L 
PCOS
8.2/7.6 B/L spill + 2.3 1.8 2.1 23.4
ovulatory 
dysfunction‐
PCOD
116 Jeyanthi 13284 27 8 RMP 161 58 22 0.6 Normal 3.5/50/40 Normal Normal 6.2/7.4 B/L spill + 2.4 1.4 2.4 17.4 Unexplained
117 Sivalochini 13756 29 7 Ireg. 144 60 30.61 0.8 Hirsutism+ 3/60/50 Normal
B/L 
PCOS
5.8/7.2 B/L spill + 2.6 1.4 2.2 19.8
ovulatory 
dysfunction‐
PCOD
118 Kalpana 13999 31 6 RMP 156 61 25 0.78 Normal 3.5/70/60 Normal Normal 6.2/8
Rt cornual block , 
B/L fimbria 
unhealthy
2.3 0.8 1.2 20.1 Tubal factor
119 Krithiga 14003 32 7 Oligomenorrhoea 150 70 31 0.82 Normal 4/80/60 Normal Normal 13.8/4.6 B/L spill + 2.1 0.9 4.4 26.4
Subclinical 
hypothyroidism
120 Srilekha 14083 30 5 RMP 160 60 23 0.62 Normal 3.5/80/50 Normal Normal 6.8/7.4
D‐LAP:B/L spill ‐ 
,e/o PID +
2.9 1.8 2.1 18.8 Tubal factor
121 Lavanaya 14132 24 4 RMP 154 58 25.77 0.74 Normal 4.2/86/50 Normal Normal 6.2/7.8 B/L spill + 2.8 1.6 6.2 16.8
Subclinical 
hypothyroidism
122 Priya 10324 26 2 RMP 160 56 21.57 0.63 Normal 1.5/10/20 Normal Normal 5.4/6.2 B/L spill + 3.8 1.6 2.1 14.4 Male Factor
123 Victoria 14454 33 10 Oligomenorrhoea 140 60 30.51 0.81
Class 1 
obesity
2.5/70/50 Normal Normal 6.2/7.8 B/L spill + 3.2 2 6.4 22.6
Subclinical 
hypothyroidism 
124 Premlatha 14666 28 7 Ireg. 150 68 30 0.82
Class 1 
obesity
3/80/60 Normal
B/L 
PCOS
4.4/6.8 B/L spill + 2.4 1.6 2.1 23.2
ovulatory 
dysfunction‐
PCOD
125 Bhagyam 14854 26 3 RMP 154 58 26 0.66 Normal 2.1/10/15 Normal Normal 5.2/6.8 B/L spill ‐ 2.8 1.2 2.3 18.4
Male 
Factor+Tubal 
Factor
126 Chitradevi 15055 31 6 RMP 154 58 25.72 0.68 Normal 2.6/78/56 Normal Normal 6.8/7.2
D‐LAP:e/o 
PID,Perotubal 
adhesions  +,B/L 
spill ‐
2.5 1.8 5.1 16.8
Subclinical 
hypothyroidism+
tubal Factor
127 Shanthi 15233 28 5 Oligomenorrhoea 160 66 25.78 0.64 Normal 3.5/70/40 Normal Normal 5.6/6.4 B/L spill + 3.2 1.6 4.5 17.4
Subclinical 
hypothyroidism
128 Teena 15429 33 8 RMP 158 54 22 0.68 Normal 4/70/50 Normal Normal 4.5/6.4 B/L spill + 3.6 1.7 2.2 16.4 Unexplained
129 Rahmad Banu 15599 32 6 Ireg. 142 64 32 0.82
Class 1 
obesity
3.5/68/40 Normal
B/L 
PCOS
7.2/6.5 B/L spill + 3.2 0.8 2.1 21.8
ovulatory 
dysfunction‐
PCOD
130 Lakshmi Devi 15854 32 6 Oligomenorrhoea 158 70 28 0.8 Normal 3/66/53 Normal Normal 5.6/6.4 B/L spill + 1.8 0.6 9.2 27.2
Subclinical 
hypothyroidism
131 Sumitha 15869 32 5 Ireg. 160 80 31 0.78
Class 1 
obesity
3.5/70/40 Normal
B/L 
PCOS
5.2/7.4 B/L spill + 3.2 1.6 2.4 20.1
ovulatory 
dysfunction‐
PCOD
132 Girija 15963 35 6 Oligomenorrhoea 156 54 22 0.7 Normal 2.4/30/50 Normal Normal 6.2/7.8 B/L spill + 3.2 1.8 5 20.8
Subclinical 
hypothyroidism 
133 Sheeja 16099 31 6 RMP 154 52 22 0.68 Normal 3/80/60 Normal Normal 5.8/7.6 B/L spill + 3.2 1.4 2.1 14.4 Tubal factor
134 Aparna 16132 29 5 RMP 158 51 20 0.6 Normal 3.2/60/40 Normal Normal 5.2/7.4 B/L Spill + 3.2 1.2 1.8 12.2 Unexplained
135 Rewathy 16236 31 3 RMP 160 52 20 0.7 Normal 1.5/10/15 Normal Normal 5.4/6.8 B/L Spill + 3.1 1.8 2.1 11.4 Male Factor
136 Renuka  16398 28 2 RMP 154 60 25 0.7 Normal 2.5/70/80 Normal Normal 6.4/7.8
D‐LAP:Unicornuate 
uterus with cornual 
fibroid
3.6 1.4 2.1 16.4 Uterine anomaly
137 Jayapriya 17435 29 2 RMP 160 58 22.65 0.7 Normal 2.5/80/60 Normal Normal 6.8/7.2 B/L spill + 3.2 1.8 6.5 18.2
Subclinical 
Hypothyroidism
138 Nandhini 17652 27 2 RMP 158 60 24 0.7 Normal 3/86/50 Normal Normal 5.8/6.4 B/L spill + 3.4 2 5.8 15.6
Subclinical 
Hypothyroidism
139 Nivedhana 17865 33 7 Ireg. 160 92 36 0.9
Class 2 
obesity
3.5/90/60 Normal
B/L 
PCOS
7.2/8.4 B/L spill + 3.6 1.8 2.3 23.1
ovulatory 
dysfunction‐
PCOD
140 Kavya 17999 31 2 RMP 162 58 22 0.7 Normal 1.1/10/20 Normal Normal 6.8/7.4 B/L spill + 3.4 2 6.2 12.4
Subclinical 
hypothyroidism+
male Factor
141 Manjula 18145 36 8 Ireg. 158 66 26 0.8 Mtx+ 2.8/30/90 Normal Normal 6.8/7.8 B/L spill + 3.2 1.9 2.3 14.4 Tubal factor
142 Monisha 18359 23 2 Oligomenorrhoea 160 72 28 0.78 Normal 3.1/67/70 Normal Normal 5.2/6.6 B/L spill + 3.6 1.7 5.8 23.4
Subclinical 
Hypothyroidism
143 Padma 18513 29 7 RMP 160 58 22.65 0.64 Normal 4.5/80/70 Normal Normal 6.4/7.8 B/L spill + 3.1 1.6 2.1 20.4 Unexplained
144 Shankari 18823 34 10 Oligomenorrhoea 158 74 30 0.86 Normal 3.5/75/40 Normal Normal 7.2/8.4 B/L spill + 2.8 1.2 4.5 24
Subclinical 
Hypothyroidism
145 Thaju Begum 19286 31 9 Ireg. 148 68 31 0.8
Class 1 
obesity
4/70/35 Normal
B/L 
PCOS
6.8/7.6 B/L spill + 3.4 1.2 2.4 22.1
ovulatory 
dysfunction‐
PCOD
146 Rosy 19541 32 5 Ireg. 160 58 22.65 0.7 RV uterus 3.5/70/50 Normal
Rt ovary 
8*6 cm 
endomet
riotic 
cyst
5.2/6.8 B/L spill ‐ 3.1 5.5 2.3 18.1 Endometriosis
147 Velankanni 19842 27 5 RMP 161 54 21 0.6 Normal 4/80/50 Normal Normal 6.2/7.4 B/L spill + 3.5 1.5 6.5 16.2
Subclinical 
Hypothyroidism
148 Srimathi 19983 29 7 Ireg. 152 74 32 0.8
Class 1 
obesity
3.5/70/40 Normal
B/L 
PCOS
5.8/6.4 B/L spill + 2.8 1.2 2.2 14.4
ovulatory 
dysfunction‐
PCOD
149 Vaishanavi 19999 26 6 Oligomenorrhoea 146 54 25 0.7 Normal 4/60/40 Normal Normal 4.4/5.8 B/L spill + 3.8 0.9 8.9 21.7
Subclinical 
Hypothyroidism
150 Sandhya 20003 31 6 Ireg. 154 72 30 0.8
Class 1 
obesity
4/75/30 Normal
B/L 
PCOS
5.2/6.6
D‐LAP:B/L spill ‐ 
,e/o PID +
2.6 1.5 2.3 19.4
Ovulatory 
dysfunction‐
PCOD+tubal 
Factor
